



**HAL**  
open science

## Forecasting individual progression trajectories in Alzheimer's disease

Etienne Maheux, Igor Koval, Juliette Ortholand, Colin Birkenbihl, Damiano Archetti, Vincent Bouteloup, Stéphane Epelbaum, Carole Dufouil, Martin Hofmann-Apitius, Stanley Durrleman

► **To cite this version:**

Etienne Maheux, Igor Koval, Juliette Ortholand, Colin Birkenbihl, Damiano Archetti, et al.. Forecasting individual progression trajectories in Alzheimer's disease. *Nature Communications*, 2023, 14 (1), pp.761. 10.1038/s41467-022-35712-5 . hal-04023781

**HAL Id: hal-04023781**

**<https://inria.hal.science/hal-04023781>**

Submitted on 10 Mar 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# FORECASTING INDIVIDUAL PROGRESSION TRAJECTORIES IN ALZHEIMER'S DISEASE

Etienne Maheux<sup>1</sup>, Igor Koval<sup>1</sup>, Juliette Ortholand<sup>1</sup>, Colin Birkenbihl<sup>2,3</sup>, Damiano Archetti<sup>4</sup>, Vincent Bouteloup<sup>5,6</sup>, Stéphane Epelbaum<sup>7</sup>, Carole Dufouil<sup>5,6</sup>, Martin Hofmann-Apitius<sup>2,3</sup>, Stanley Durrleman<sup>1</sup>

<sup>1</sup> Sorbonne Université, Institut du Cerveau - Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France

<sup>2</sup> Department of bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany

<sup>3</sup> Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn 53115, Germany

<sup>4</sup> IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

<sup>5</sup> Université de Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Bordeaux, France

<sup>6</sup> Centre Hospitalier Universitaire (CHU) de Bordeaux, pôle de neurosciences cliniques, centre mémoire de ressources et de recherche, Bordeaux, France

<sup>7</sup> Sorbonne Université, Institut du Cerveau - Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital Pitié-Salpêtrière, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), center of excellence of neurodegenerative diseases (CoEN), department of Neurology, DMU Neurosciences, Paris, France

Correspondence to:

Stanley Durrleman, Paris Brain Institute, Pitié-Salpêtrière Hospital - CS21414, 75646 PARIS Cedex 13 France  
tel: +33 57 27 43 80, e-mail: [stanley.durrleman@inria.fr](mailto:stanley.durrleman@inria.fr), ORCID: 0000-0002-9450-6920

## ABSTRACT

The anticipation of progression of Alzheimer's disease (AD) is crucial for evaluations of secondary prevention measures thought to modify the disease trajectory. However, it is difficult to forecast the natural progression of AD, notably because several functions decline at different ages and different rates in different patients. We evaluate here AD Course Map, a statistical model predicting the progression of neuropsychological assessments and imaging biomarkers for a patient from current medical and radiological data at early disease stages. We tested the method on more than 96,000 cases, with a pool of more than 4,600 patients from four continents. We measured the accuracy of the method for selecting participants displaying a progression of clinical endpoints during a hypothetical trial. We show that enriching the population with the predicted progressors decreases the required sample size by 38% to 50%, depending on trial duration, outcome, and targeted disease stage, from asymptomatic individuals at risk of AD to subjects with early and mild AD. We show that the method introduces no biases regarding sex or geographic locations and is robust to missing data. It performs best at the earliest stages of disease and is therefore highly suitable for use in prevention trials.

## INTRODUCTION

The cost of drug development is highest, by far, for neurodegenerative diseases, with unparalleled failure rates<sup>1</sup>. In this respect, the controversial approval of aducanumab on June 7, 2021 by the Food and Drug Administration (FDA) represents a turning point in Alzheimer's disease (AD) drug development<sup>2</sup>. This decision raises the critical issue of demonstrating the clinical benefit of a compound acting on a key biological process, the accumulation of amyloid plaques in the brain<sup>3</sup>.

It remains unclear why an effective intervention for such a key biological mechanism is only weakly associated with lower levels of cognitive decline. It is likely that the core biological processes and their interactions are not yet fully understood. Another, non-exclusive explanation is that the issue of who and when to treat must be addressed with greater precision to demonstrate clinical efficacy. In 2019, Cummings and coworkers were already stressing the need to improve clinical trials, by targeting the right participant with the right biomarker in the right trial<sup>4</sup>. The motivation, here, is simple: it is not possible to show that a candidate therapy slows down the degradation of the endpoint if this endpoint is not expected to worsen during the trial. The treatment effect size will be larger if one includes participants right before the disease progression would cause a significant change of the endpoint without an intervention. Such a target period depends on the endpoint selected to demonstrate efficacy.

It is particularly difficult to identify the most appropriate time frame for a disease like AD, which progresses over decades, in a non-linear manner, and with different clinical presentations between patients. The thresholds currently used for the main biomarkers and clinical endpoints are not sufficiently effective for the selection of patient populations with homogeneous progression profiles<sup>5</sup>. Disease modeling uses computational and statistical methods to address this question<sup>6-14</sup>. These models learn the variability of disease progression from observational longitudinal cohort data and can then predict the progression of patients from their historical data. They require various clinical or biomarker assessments at one or several time points as input. These techniques are beginning to be evaluated for clinical trial design. For example, a retrospective analysis showed that the effect size of a treatment could be increased by targeting participants with a predicted type of progression at trial entry<sup>15</sup>. Other studies indicated that predicting the value of endpoints might make it possible to reduce sample sizes in clinical trials<sup>16,17</sup>.

We propose here a software tool using a disease progression model for participant selection in clinical trials. The goal is to enrich the selected population in participants likely to display progression during the trial, a concept called prognostic enrichment<sup>18</sup> by the FDA and already applied in some AD trials<sup>19,20</sup>. We will use AD Course Map as a disease progression model. It is a non-linear mixed-effect model, which predicts both the dynamics of progression and the clinical presentation of the disease<sup>21,22</sup>. This technique outperformed the 56 alternative methods for predicting cognitive decline in the framework of the TADPOLE challenge<sup>6,23</sup>. We will compare this model with RNN-AD, which is a recurrent neural network, namely a deep learning method that learns temporal dynamic behavior. In June 2020, it ranked 2<sup>nd</sup> for the prediction of cognitive decline in the TADPOLE challenge<sup>24</sup>.

We will first evaluate the ability of the model to predict progression for the main endpoints used as outcomes in current clinical trials. We will use five independent data sets with data from more than 4,600 patients spread over four continents. We will analyze the systematic biases of such algorithms, their robustness to missing data and suitability for generalization across countries, ethnicities and disease stages. Finally, we will simulate inclusion procedures for clinical trials by varying several key parameters: the chosen outcome, trial duration, and the selection criteria. Finally, we will show that participants predicted to be at risk of the outcome worsening constitute a population likely to show a greater and more homogeneous response to treatment.

## RESULTS

### *Characteristics of the study population*

We used data of 4,687 participants from five longitudinal multicenter cohorts from North America, Australia, Japan, and Europe: the Alzheimer's disease neuroimaging initiative (ADNI)<sup>25-31</sup> (N=1,652), the Australian imaging, biomarker and lifestyle flagship study of aging (AIBL)<sup>32,33</sup> (N=460), the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI)<sup>34,35</sup> (N=470), the PharmaCog cohort<sup>36,37</sup> (N=111) and the MEMENTO cohort<sup>38</sup> (N=1,994). Each study enrolled participants attending memory clinics.

Table 1 and 2 summarize the characteristics of each data set. These data sets contain diverse patient profiles from different ethnic, genetic and geographic backgrounds, with follow-up visits at different disease stages. For all these studies, the neuropsychological examinations were performed in accordance with international standards, and the image acquisition procedures were performed in accordance with the protocols established by the ADNI consortium. Together, these data sets therefore correspond to a relevant pool of patients for simulating inclusion procedures for a typical large multicenter phase III trial.

### *Disease progression models learn the timing of changes in biomarker levels during disease progression*

We train disease progression models using the ADNI participants with confirmed pathological amyloid levels as the training set (N=866) with baseline and all available follow-up data. We kept the data from the other ADNI participants and the members of the four external cohorts as the validation set (N=3,821). The same protocol for training and validating the models is used for AD Course Map and RNN-AD. See Methods for details.

The two models include the following endpoints: Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale - cognitive subscale with 13 items (ADAS-Cog13), Clinical Dementia Rating – sum of boxes (CDR-SB), volumes of the left and right hippocampus and lateral ventricles,  $A\beta_{1-42}$  and p-tau<sub>181</sub> levels in the cerebrospinal fluid (CSF), standard uptake value ratio (SUVR) for Amyloid PET and Tau PET scans. See Methods for details.

AD Course Map assumes that these endpoints follow a logistic progression curve during disease progression with distinct progression rate and age at the inflexion point<sup>21,22</sup>. It learns how this set of logistic curves need to

be adjusted to fit individual data by changing the dynamic of progression and disease presentation (i.e. the relative value of the endpoints at a given disease stage). By contrast, RNN-AD learns how the values of the endpoints will change in the next month given the values of the endpoint at a given time-point. The 1-month transition is assumed to be a non-linear function (e.g. a neural network) of the current value of the endpoints and the current diagnosis. Supplementary Table 1 shows the goodness-of-fit on the training set, consistent with the results of our previous studies on AD Course Map<sup>6</sup> and RNN-AD<sup>24</sup>. See Methods for details.

### ***Disease progression models forecast cognitive decline***

The disease progression models predict the subject-specific trajectory of biomarker changes from data collected from the subject concerned at one or several visits. The predicted trajectory is used to forecast the values of the biomarkers at future time points. Figure 1 illustrates this forecast procedure.

We repeatedly assessed the errors of AD Course Map and RNN-AD for forecasting cognitive endpoints (ADAS-Cog13, MMSE and CDR-SB) for participants in the validation set. We blinded the latest visits of the participants and tried to predict them from the unblinded data (see Supplementary Figure 1 and Methods for details of the procedure). From 44,435 forecasts for ADAS-Cog13 (96,970 for MMSE and 96,849 for CDR-SB), we determined the absolute difference between predicted and actual results as a function of the characteristics of the participants and the information used for forecasting purposes.

Figure 2 shows the distribution of mean absolute errors (MAE) for AD Course Map and RNN-AD adjusted for confounding factors. The reported errors are for the reference participant in the reference forecast design: a 75-year-old American woman from the ADNI cohort with an average education level, no APOE-ε4 mutations and an A+T+N+ status with a questionable dementia (CDR = 0.5 noted C~), for whom we forecast neuropsychological assessments in three years' time, based on two past visits separated by eight months with no missing data. AD Course Map yields a mean absolute error of 5.98 (95% CI=[5.44, 6.48]) on a scale of 85 for ADAS-Cog13, of 2.54 (95% CI=[2.39, 2.71]) on a scale of 30 for the MMSE, and of 1.86 (95% CI=[1.75, 1.99]) on a scale of 18 for the CDR-SB.

On all occasions, AD Course Map and RNN-AD yielded significantly smaller errors than two alternative methods: no-change prediction (predicting the same value as obtained at the participant's last visit) and a linear mixed-effects model ( $p < 0.01$  for both, see Supplementary Table 2). These two alternatives were shown to be good predictor of short-term progression, essentially because of the overall slow pace of progression of the disease<sup>6,23</sup>. The deep learning method RNN-AD yields intermediate performance with adjusted mean absolute errors of 6.53 (95% CI=[6.02, 7.19]), 2.75 (95% CI=[2.57, 2.92]), and 1.95 (95% CI=[1.81, 2.09]) for the prediction of ADAS-Cog13, MMSE and CDR-SB respectively.

We investigated the change in MAE for ADAS-Cog 13 score for different categories of participants and forecast designs (Figure 3). For AD Course Map, the number of previous visits considered (1, 2 or 3) did not significantly affect forecasting error. By contrast, for every additional year of time to prediction, MAE for

ADAS-Cog13 score increased by 0.80 (95% CI=[0.71, 0.93]). Forecasts were not significantly affected by sex nor APOE genotype but were slightly improved for participants who are older than average and had longer education. On average, the forecasts for the European participants from PharmaCog cohort as well as the Japanese participants from the J-ADNI cohort were better than those for the American participants from the ADNI cohort, by about 1.1 and 0.6 points respectively. Forecasts were robust to missing CSF or Tau PET data, and slightly worsened when MRI or Amyloid PET were missing with differences in MAE of 0.27 (95% CI=[0.00, 0.55]) and 0.54 points (95% CI=[0.15, 1.02]) respectively. The model forecasts better at earlier stages of the AD continuum than at later clinical stages (Figure 3a). The method was readily generalizable to the included participants with suspected non-amyloid pathology (SNAP) and possible concomitant pathological non-Alzheimer's changes.

Similar conclusions were drawn for predictions of MMSE and CDR-SB (see Supplementary Figures 2 and 3). AD Course Map performed better on all but one external validation cohort. Errors were robust to changes in the available information used to make the prediction, such as the number of unblinded visits and missing data. This method did not produce biased forecasts for women. Forecasts for those two endpoints however displayed slightly worse results for participants older than average or with an education level that is below the average, and for APOE-ε4 carriers.

### ***Disease progression models select participants displaying progression for trials***

We now use disease progression models to identify the participants likely to experience significant cognitive decline during a trial (see Figure 4). The definition of participants displaying progression depends on the endpoint used to measure the condition and the duration of the trial. We simulated six clinical trials with different primary outcomes, trial durations and inclusion criteria. These designs were inspired by real phase III trials (see Table 3).

For each trial, we selected the participants in the validation set who met the inclusion criteria at one of their visits (considered as the baseline visit for the simulated trial) and attending a follow-up visit after a period equal to the theoretical duration of the trial. We split this population into two equal halves: fast and slow progressors, according to whether the outcome considered (e.g. the annual change in endpoint relative to baseline) was above or below the population median value. We aimed to identify the participants in these two groups exclusively on the basis of their baseline data.

We used the disease progression models to forecast the values of the endpoint at the end of the trial from the baseline data for each participant. The predicted outcome was used as a prognostic score. For AD Course Map, Pearson correlations with the true outcome range from 28% to 47% depending on the trial, while for RNN-AD they range from 13% to 36% (see Supplementary Table 3). Participants with a prognostic score above a given threshold were considered to be likely to be fast progressors. We plotted receiver operating characteristics (ROC) curves for the six simulated trials (Figure 5). The area under the ROC curve (AUC) of the six simulated trials fell within the 65%-80% range for AD Course Map and within the 55%-80% range for RNN-AD (see Figure 5).

We compared this prognostic enrichment strategy with two alternative methods: selecting participants at random (bisector of the ROC curve) as currently done in most trials, or selecting participants based on their APOE genotype (gray crosses in Figure 5). All selection methods were significantly better than random selection, meaning that disease progression models succeed in identifying the progressors compared to the current practice that does make any difference among the participants meeting the inclusion criteria. In all but one case, selections with AD Course Map were significantly better than selection on the basis of APOE genotype. RNN-AD also compares favorably against the two alternatives. Nevertheless, it has significantly worse performance than AD Course Map in two out of six tested scenarios, with a drop of 9% and 14% in the ROC AUC. AD Course Map shows therefore more robust results than RNN-AD when the trial design is varied.

We analyzed whether our assessment of the risk of progression led to an over- or under-selection of certain types of participants relative to the true progressors (see Supplementary Figure 4). Depending on the design, the group that was selected using AD Course Map displayed slight enrichment in men or women, and tended to be biased towards older participants. The selected participants were often, but not always, enriched in carriers of the APOE- $\epsilon$ 4 variant. The presented disease progression models do not use sociodemographic or genetic factors as proxies for the selection of participants displaying progression. They limit therefore the biases of sex, age or APOE- $\epsilon$ 4 carriership, which are the basis of current practices to increase the likelihood that a participant progresses during a trial.

### ***Disease progression models can be used to design more powered clinical trials***

The automatic selection of participants displaying progression makes it possible to implement prognostic enrichment strategies in trials (see Figure 4). For each trial design, we simulated a hypothetical treatment decreasing the outcome value. We calculated the sample size required to show an effect of this treatment for a range of treatment effects (see Methods). We compared the results when all eligible participants were included to those obtained when only participants predicted to be fast progressors at baseline were included.

We plotted sample size against treatment effect for all six simulated trials (Figure 6). The selection of participants at risk of progression with AD Course Map allowed a significant reduction in sample size relative to current inclusion criteria alone, across all scenarios tested. For a treatment effect of 25%, sample size was reduced by 50.2% ( $\pm$  7.1) for participants at risk of the onset of AD, by 40.9% ( $\pm$  4.9) for a trial targeting individuals with preclinical AD and high brain amyloid levels, by between 38.1% ( $\pm$  1.6) and 45.4% ( $\pm$  2.0), depending on the outcome considered, for subjects with early AD and high levels of brain amyloid, by 44.6% ( $\pm$  3.9) for subjects with early AD and high brain levels of tau, and by 43.1% ( $\pm$  0.8) for participants with mild cognitive impairment probably due to AD or mild AD.

For all preclinical and early AD trials, enrichments based on AD Course Map significantly outperformed the selection of APOE- $\epsilon$ 4 variant carriers only. For mild cognitive impairment due to AD or a mild AD trial, the performance of enrichment based on AD Course Map was not significantly different from targeting APOE- $\epsilon$ 4 carriers. AD Course Map achieved a similar decrease in sample size, but without the need to target a specific



genetic profile. In this case, we also found that 49.2% (95% CI=[48.6, 49.9]) of the participants would be selected by AD Course Map, versus 39.1% (95% CI= [38.7, 39.4]) for heterozygous APOE-ε4 carriers, facilitating recruitment with AD Course Map (see Supplementary Table 4).

RNN-AD also allowed significant reduction of the sample size compared to current practice, from 21% to 42% depending on the tested scenario. Nevertheless, the reduction was never better than with AD Course Map with an increase of 10% and 35% participants to be selected for the two scenarios where RNN-AD yielded a lower AUC (see Supplementary Table 5).

## DISCUSSION

We used disease progression models to forecast cognitive decline across all stages of the AD continuum. Using five independent cohorts containing more than 4,600 participants, we show here that AD Course Map provides a fair, robust, and generalizable predictive method. It is fair, in that its predictions are not biased with respect to sex, and are only marginally affected by level of education and the age of the participant. The method is robust to missing CSF or Tau PET biomarkers, but in general better results are achieved when MRI and Amyloid PET data are present. The model was trained on data acquired in North America, but it is readily generalizable to participants from Europe, Asia, and Oceania, with no loss of performance. It performed better at the earliest preclinical stages of the AD continuum than at later disease stages, and is therefore relevant for early-stage interventions.

Disease progression models automatically identify the participants already at risk of experiencing cognitive decline at baseline in a trial. They can therefore be used to enrich the trial population in participants likely to experience a worsening of a given endpoint during the trial. By targeting more homogeneous groups of participants displaying progression, AD Course Map makes it possible to decrease sample size significantly, by 38% up to 50%, at the expense of discarding about half of the screened participants. It shows better and more robust performance than the deep learning method RNN-AD. Disease progression models adapt seamlessly to various clinical trial designs targeting different disease stages with different outcomes and trial durations. They do so without the need to re-train the model for each new trial. In comparison, a recent method based on another prognosis score reported sample size reductions of 20% to 28%<sup>17</sup>.

The main limitation of the method is the data used to monitor disease progression. Cognitive assessment displays about 10% inter-rater variability<sup>39-41</sup>. MRI biomarkers also display a similar degree of variability between two scans acquired on the same day for the same participant, and their reliability is further decreased by possible variations in the processing pipelines<sup>42</sup>. Mapping CSF biomarkers from different immunoassays also limits their reliability<sup>43</sup>. These factors limit the accuracy of the method for forecasting disease progression. Increasing the reliability of these measurements would improve the performance of the approach described here. In the future, disease progression models such as AD Course Map may also benefit from the inclusion of promising new biomarkers, such as plasma biomarkers, neurofilament light chain<sup>44</sup> or digital biomarkers<sup>45</sup>.

Given these limitations, it is notable that such large sample size reductions can be achieved with data already available in routine clinical practice. These findings demonstrate the benefits of companion software tools for patient recruitment in trials and for supporting clinicians in the future, enabling them to prescribe the right treatment to the right patient at the right time.

## METHODS

### *Participants*

We used the data from five longitudinal multicenter cohorts: the Alzheimer's disease neuroimaging initiative (ADNI)<sup>25-31</sup> (N=1,652), the Australian imaging, biomarker and lifestyle flagship study of aging (AIBL)<sup>32,33</sup> (N=460), the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI)<sup>34,35</sup> (N=470), the PharmaCog cohort<sup>36,37</sup> (N=111) and the MEMENTO cohort<sup>38</sup> (N=1,994).

The study protocols were approved by the ethical committees of the university of southern California (ADNI), Austin Health, St Vincent's Health, Hollywook Private Hospital and Edith Cowan University (AIBL), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli (PharmaCog), Comité de protection des personnes sud-ouest et outre-mer III (MEMENTO), the National Bioscience Database Center Human Database (J-ADNI). Informed consent forms were obtained from research participants. The research has been performed in accordance with the Declaration of Helsinki and relevant guidelines and regulations. Participants were not compensated for the current study.

The five cohorts are longitudinal observational studies with an average observation period ranging from 2.0 years for PHARMACOG to 4.8 years for ADNI, with an average number of visits ranging from 3.7 in AIBL to 6.9 in MEMENTO. We considered all participants with at least one year of follow-up. The socio-demographic, genetic, biological and clinical characteristics of the selected participants are reported in Table 1 and 2, as well as the proportion of available data in each cohort.

### *Neuropsychological assessments*

In our experiments, we considered the following neuropsychological assessments:

- The mini-mental state examination<sup>39</sup> (MMSE),
- The Alzheimer's disease assessment scale – cognitive subscale with 13 items<sup>40,46</sup> (ADAS-Cog13),
- The clinical dementia rating scale<sup>41,47</sup> – sum of the boxes score (CDR-SB).

### *Structural magnetic resonance imaging/anatomical imaging biomarkers*

We extracted cortical and subcortical volumes from three-dimensional T1-weighted magnetization-prepared rapid gradient-echo imaging (MPRAGE) sequences.

For the ADNI study, scans were acquired in the standardized protocol for morphometric analyses (<http://adni.loni.usc.edu/methods/documents/mri-protocols/>). The ADNI MRI core processed raw scans, using Gradwarp for the correction of geometric distortion due to gradient nonlinearity<sup>48</sup>, B1-correction for the adjustment of image intensity inhomogeneity<sup>26</sup>, N3 bias field correction for reducing residual intensity inhomogeneity<sup>49,50</sup>, and geometric scaling for adjusting scanner- and session-specific calibration errors<sup>26,51</sup>. The same MRI protocol was also used in AIBL<sup>32</sup>, J-ADNI<sup>52</sup>, PharmaCog<sup>36</sup>, and MEMENTO<sup>38,53</sup>.

For all studies, cortical reconstruction and volumetric segmentation were performed with the Freesurfer image analysis suite (<http://surfer.nmr.mgh.harvard.edu/>). Version 5.3 was used for J-ADNI, MEMENTO and PharmaCog, and version 6.0 for ADNI and AIBL, operated within Clinica for reproducibility purposes<sup>54</sup>. The cohort effect in the following analyses accounts for possible differences due to different versions of the software.

We calculated the mean volume of the left and right hippocampus, and the total volume of the lateral ventricles (including inferior lateral volume). Hippocampus segmentation with Freesurfer was previously reported to have good reproducibility<sup>55,56</sup>. Both volumes were normalized by estimated total intracranial volume (ICV).

### ***Cerebrospinal fluid biomarkers***

We used the concentrations in cerebrospinal fluid (CSF) of  $\beta$ -Amyloid 1–42 peptide ( $A\beta_{1-42}$ ), Tau protein, phosphorylated at the threonine 181 residue (p-Tau<sub>181</sub>), and total tau protein (t-Tau).

ADNI used the automated Elecsys immunoassay (Roche); AIBL, PharmaCog and MEMENTO used INNOTEST single-analyte ELISA tests (Innogenetics/Fujirebio NV), and J-ADNI used the multiplex xMAP Luminex platform with the INNO-BIA AlzBio3 immuno-assay kit (Innogenetics/Fujirebio NV).

We harmonized the measurements to account for the differences in immuno-assays and participants characteristics across cohorts. Within each cohort, we regressed each biomarker against age, APOE genotype, and CDR global score with a linear mixed model with random intercept. We then linearly transformed the measurements so that the intercept is 0 and the total variance is 1 for all cohorts. Harmonization equations used are listed in the Supplementary Table 6 for reproducibility purposes.

### ***Positron emission tomography/functional imaging biomarkers***

For ADNI participants, we used regional standardized uptake value ratios (SUVR) extracted from Amyloid PET scans (<sup>18</sup>F]-Florbetapir and <sup>18</sup>F]-Florbetaben radiotracers), and, starting from ADNI 3, Tau PET scans (<sup>18</sup>F]-AV-1451 radiotracer). Each PET scan was registered together with the MRI for the subject performed as close as possible to the PET scan in terms of time.

For Amyloid PET, we used a cortical summary region consisting of the frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal regions; data were normalized with a composite reference region consisting of the whole cerebellum, brainstem/pons, and eroded subcortical white matter<sup>57–59</sup>. These PET SUVR values were converted to the centiloid scale (CL)<sup>60</sup> using equations from the literature<sup>61</sup> listed in the Supplementary Table 6. In the AIBL cohort, the processed Amyloid PET SUVR data that correspond to the published centiloid conversion equations were not publicly available. In the MEMENTO cohort, Amyloid PET SUVR data are not directly comparable with ADNI data and equations for centiloid conversion were not available. Therefore, we

used Amyloid PET data on these cohorts only to define the Amyloid status of the participants, using pathological thresholds provided by these studies.

For Tau PET, we used a volume-weighted average SUVR value for all anatomical Braak regions of interest (I-VI)<sup>62</sup>, normalized against the inferior cerebellum gray matter<sup>63</sup>.

### *A/T/N/C classification*

We classified participants with the A(myloid)/T(au)/N(eurodegeneration) classification<sup>64,65</sup>, together with a C(ognition)/C(linical) group based on the Clinical Dementia Rating (CDR) global score (see the Supplementary Table 7 for all thresholds used). Participant category at a given visit was based on the patient's all-time worst biomarker levels to date. Incomplete A/T/N/C profiles are denoted with a star after any of the biomarkers that could not be determined.

### *Disease progression models*

We trained and tested two disease progression models: AD Course Map and RNN-AD. AD Course Map is built on the principles of a parametric Bayesian non-linear mixed-effects model<sup>21,22</sup>. RNN-AD is built on the principles of recurrent artificial neural networks<sup>24,66</sup>. The implementation of both models relies on the open-source software that were made publicly available by their respective authors.

Both models use the same set of endpoints as input: MMSE, CDR-SB, ADAS-Cog13, volume of the left and right hippocampus and lateral ventricles, CSF A $\beta_{1-42}$  and p-tau<sub>181</sub> levels, together with cortical-summary SUVR on Amyloid PET and Tau PET scans. They consider these endpoints at one or several visits of a participant, allowing for possible missing data, and predict the value of all these endpoints at any time-point in the future. AD Course Map also takes into account the age of the participant at each visit, while RNN-AD takes into account only the duration between two consecutive visits, irrespective of the age of the participant. In addition, RNN-AD needs the diagnosis of the participant at the corresponding visit, the diagnosis being cognitively normal, mild cognitive impairment or demented, as defined in the ADNI protocol.

AD Course Map assumes that these endpoints follow a logistic progression curve during disease progression with distinct progression rate and age at the inflexion point<sup>21,22</sup>. It learns how this set of logistic curves need to be adjusted to fit individual data, by changing the dynamic of progression and disease presentation (i.e. the ordering and timing of progression among the endpoints). The shape and position of the reference set of logistic curves are the fixed effects, the parameters changing these curves to fit individual data are the random effects. The model parameters (fixed effects together with the mean and variance of the random effects) are estimated using a training data set containing the repeated measurements of a multitude of participants. After the training phase, the model is fit to the measurements of one test participant (outside the training test) at one or several visit, using the learnt distribution of the random effects as a regularizer. As a result, the model predicts a subject-specific set of logistic curves, which shows the value of each endpoint at any age of the participant.

By contrast, RNN-AD does not make any assumption on the life-long pattern of progression of the endpoints. It learns instead how the values of the endpoints will change in the next month given the values of the endpoint at a given time-point. The 1-month transition is assumed to be a non-linear function of the current value of the endpoints and the current diagnosis (e.g. artificial neurons). The parameters of this transition function are estimated using a training data set containing the repeated measurements of a multitude of participants. After the training phase, the measurements of one test participant (outside the training set) at one or several visits are used as input of the model. The model then computes the values of all the endpoints at each month in the future.

AD Course Map can be trained and tested with missing data: the likelihood is optimized using the available data only. Model training is robust to missing data<sup>6</sup>, so we did not perform data imputation. By contrast, RNN-AD needs complete data at the baseline visit. We imputed missing data with the mean value of the endpoint in the training set, following authors' recommendations<sup>24</sup>; missing data at subsequent visits are imputed recurrently using model predictions.

Both models also need an internal step of data normalization. For AD Course Map, cognitive assessments were normalized to a 0 to +1 scale according to the theoretical minimum and maximum values of each assessment, 0 representing the theoretical best value (unaffected participants) and +1 the worst possible value. Harmonized amyloid PET data are clipped between 0 and 100 and converted to a (0,1) scale. MRI, tau PET, and Harmonized CSF data were clipped at the first and last centile, and then linearly mapped to a (0,1) scale. For RNN-AD, normalization consists in a z-score transformation estimated from training data.

Regardless of the normalization procedure, the outputs of the models are always converted back to the native scale (and unit) of the measurement before being analyzed (see Figure 1). Predicted values are therefore comparable with the true, non-normalized data. Forecast errors can be compared across methods that do not use the same normalization procedure.

### ***Validation procedure***

We split the data sets in two (see Supplementary Figure 1). We first considered the ADNI participants who were amyloid-positive according to CSF or PET data on at least one visit (shown in red in the Supplementary Figure 1). We then kept the other ADNI participants and all participants from the four other cohorts as an external validation set (shown in blue in the Supplementary Figure 1).

We then split the amyloid positive ADNI participants in 5 random folds and trained AD Course Map and RNN-AD using all available data of the participants in 4 out of the 5 folds, e.g. the training set. We repeated this procedure with another split, so that we ended up with 10 instances of each model. Each participant has been counted twice as a test subject in the left-out fold. Therefore, it can be used twice for evaluating prediction tasks with two different instances of each model. By contrast, each participant in the external validation set can be tested with 10 different instances of each model. In the following, we averaged the prediction made by the 2 instances of the model for the participants in the test sets, and by the 10 instances for the participants in the external validation set.

The test subjects did not contribute to any model selection or hyperparameter tuning neither for AD Course Map nor for RNN-AD. Therefore, we pooled the forecasts of test subjects with the ones in the external validation set.

### ***Forecasting endpoints***

We aimed to assess the accuracy of each model to forecast the values of the endpoints of a participant in the test set or the external validation set. The general principle is to blind the latest data of the participant, use the unblinded data as input of the model, and compare the predicted value with the blinded data.

We used a combinatorial procedure to generate prediction tasks, as described in the Supplementary Figure 1. Because we have multiple follow-up visits, we assessed several forecast errors for a single participant: we blinded the data of the participant except at one to three consecutive visits, we predict the individual trajectory using the unblinded data, and forecast the data at the blinded visits after the latest unblinded visit. We required that the participants are between 50 and 90 years old and have a CDR global of at most 2 at the latest unblinded visit to exclude severely demented participants, and that the blinded visits used to assess the forecast fall between 1.4 and 6.6 years after the latest unblinded visit. We computed the forecast error as the absolute difference between this value and the value of the endpoint at the follow-up visit concerned.

### ***Analysis of forecast errors***

We analyzed the distribution of mean absolute errors with a mixed-effects model. We corrected the errors for several possible confounding factors and accounted for the fact that multiple forecasts originated from the same participant. In practice, for a given endpoint and a given model, we performed the following procedure 100 times:

- We randomly picked a subset of disjointed prediction tasks, namely predictions not sharing any common visit (neither the blinded visit to forecast, nor the unblinded visits used to forecast);
- We fit a multivariate linear mixed-effects model with a random intercept for each individual, using the following categorical explanatory variables: A/T/N/C stage at prediction, cohort, number of APOE- $\epsilon$ 4 alleles, sex, level of education, number of unblinded visits, and continuous explanatory variables: actual patient's age at prediction centered on 75 years and normalized by 7.5 years, years to prediction centered on three years and normalized by one year, mean time between unblinded visits centered on eight months and normalized by three months, percentage of missing data for the unblinded visits per modality.

Education level was classified as low if the subject had followed no more than nine years of formal education and high if the subject had followed at least 16 years of education, in accordance with the guidelines of the international standard classification of education (ISCED) of the United Nations.

We derived the mean and empirical confidence interval for the model intercept (the mean absolute error adjusted for confounding factors) and regression coefficients (association between the mean absolute errors and each confounding factor).

### ***Comparison with alternative methods***

We also compared AD Course Map with two additional alternative methods. The first, the no-change prediction or last-observation-carried-forward method, forecasts the future value of an endpoint to be the same as it was at the last unblinded visit. The second method, the linear mixed model method, involved generating a linear mixed-effects model for each endpoint, regressing endpoint values against the age of the participant at the successive visits, with a random intercept and a random slope per subject. The model was fitted to an unseen participant with a maximum a posteriori estimator<sup>67</sup>. We used the same validation procedure for all models: AD Course Map, RNN-AD, no-change prediction and the linear mixed model.

### ***Clinical trial simulation, enrichment evaluation, and sample-size calculation***

We simulated clinical trials in subjects at risk of developing AD or at an early stage of AD, as described in Table 3. For each trial, we selected all pairs of visits from all participants in the five data sets satisfying the following criteria:

- The primary endpoint of the trial was assessed at both visits,
- The patient fulfilled the inclusion criteria and had none of the exclusion criteria of the trial at the baseline visit,
- Visits were separated by the duration of the trial, with a certain tolerance, depending on the trial.

For each pair of visits, the first was considered to be the baseline visit at inclusion and the second was considered to be the visit at the end of the trial. We did not take into account possible intermediate visits. Supplementary Table 8 summarizes the characteristics of participants included in all the simulated trials.

We first evaluated our prognostic enrichment strategy from a diagnostic test standpoint. For each trial, we forecast the value of the primary endpoint at the follow-up visit from the baseline data only, using the procedure described above. We calculated the median value of the outcome (i.e. the annual rate of change between baseline and follow-up visit). Participants above this threshold were considered to be fast progressors and formed the target population to be identified. A threshold for predicted outcomes was used to split the population into two groups: one considered at high risk of progression and the other at low risk of progression. We let the low-risk vs. high-risk threshold vary and calculated the resulting receiver operator characteristic (ROC) curve. On this curve, we identified the point splitting the population into a low-risk and a high-risk group of equal sizes, which was used as the operating point. We determined confidence intervals by performing our analyses 100 times on half the samples selected at random. Within any given run, any visit of a patient was used no more than once. The regions of confidence around ROC curves were constructed graphically as envelopes of both sensitivity and specificity confidence intervals along thresholds.



We evaluated possible biases in the group at high risk of progression. We used a logistic regression predicting selection status from population covariates (age, sex, education, number of APOE- $\epsilon$ 4 alleles), cohort, and missing baseline modalities, together with the true indicator of fast progression. This last binary predictor was included to check for biases emerging in addition to the biases naturally present in the target population.

We then evaluated our prognostic enrichment strategy by calculating statistical power. We used a hypothetical individual treatment model: if the outcome actually worsened between baseline and follow-up for the participant, we changed the annual rate of change by the treatment effect, e.g. a 20% improvement of the annual rate of change. We did not apply a treatment effect if the participant improved between baseline and follow-up. For treatment effects ranging from 20% to 30%, we computed effect size (Cohen's  $d$ ) and sample size from a two-independent sample asymptotic  $t$ -test, with a 5% bilateral level of significance and 80% statistical power. We compared this sample size for the population selected with the trial inclusion criteria alone, and for the subpopulation identified as at high risk of progression. We reported the total sample size for two arms. We did not account for the drop-out rate in the calculation, as the goal was to compare statistical power with and without enrichment.

In these two experiments, we compared the results obtained with those for a method selecting APOE- $\epsilon$ 4 carriers (heterozygous or homozygous) as participants at high risk of progression. We were unable to use this method for the trial targeting participants at risk of the onset of AD since this trial included only APOE- $\epsilon$ 4 carriers.

### ***Statistics and reproducibility***

No statistical method was used to predetermine sample size. We considered all available data from all the cohorts and excluded only the data of the participants with less than one year of follow-up. The experiments were not randomized since only observational data were used. The investigators were not blinded to allocation during experiments and outcome assessment since only observational data were used. Simulations of clinical trials included a random unblinded allocation into treated and control arms with assessment of biases in sex, center, level of education and APOE genotype.

## **DATA AVAILABILITY**

The ADNI and AIBL data used in this study are available in the database of the laboratory of neuroimaging at the university of Southern California under accession code at <http://adni.loni.usc.edu>.

The J-ADNI data used in this study are available in the NBDC Human Database under accession code at <http://humandbs.biosciencedbc.jp/en/>.

The PharmaCog data used in this study are available in the NeuGRID2 platform under access code at <https://www.neugrid2.eu/> (<https://doi.org/10.17616/R31NJN1E>)

The MEMENTO data used in this study are available in Dementia Platform UK under accession code at <https://portal.dementiasplatform.uk/CohortDirectory/Item?fingerPrintID=MEMENTO>

Raw data and patient-level data that were generated in this study are protected and are not available due to data privacy laws and data use agreements. These data can be re-generated using the open-source software Leaspy

(see below) by anyone with an authorized access to the above third-party data. The data used to compute the statistics in this study are available in a dedicated Zenodo repository<sup>68</sup>. Source data are provided with this paper.

## CODE AVAILABILITY

The statistical analysis of the forecast errors and the simulation of clinical trials were performed in Python. We used the Leaspy open-source software (<https://gitlab.com/icm-institute/aramislab/leaspy>) for training and testing AD Course Map, and the corresponding open-source software for RNN-AD [https://github.com/ThomasYeoLab/CBIG/tree/master/stable\\_projects/predict\\_phenotypes/Nguyen2020\\_RNNA](https://github.com/ThomasYeoLab/CBIG/tree/master/stable_projects/predict_phenotypes/Nguyen2020_RNNA). Linear mixed models were trained using the open-source *statsmodels* package<sup>69</sup>. The software code can be found in a dedicated Zenodo repository<sup>68</sup>.

## REFERENCES

1. Cummings, J., Reiber, C. & Kumar, P. The price of progress: Funding and financing Alzheimer's disease drug development. *Alzheimers Dement. Transl. Res. Clin. Interv.* **4**, 330–343 (2018).
2. Schneider, L. A resurrection of aducanumab for Alzheimer's disease. *Lancet Neurol.* **19**, 111–112 (2020).
3. Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A. & Sabbagh, M. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. *Alzheimers Res. Ther.* **12**, 95 (2020).
4. Cummings, J., Feldman, H. H. & Scheltens, P. The “rights” of precision drug development for Alzheimer's disease. *Alzheimers Res. Ther.* **11**, 76 (2019).
5. Jutten, R. J. *et al.* Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. *Neurology* **96**, e2673–e2684 (2021).
6. Koval, I. *et al.* AD Course Map charts Alzheimer's disease progression. *Sci. Rep.* **11**, 8020 (2021).
7. Iddi, S. *et al.* Predicting the course of Alzheimer's progression. *Brain Inform.* **6**, 6 (2019).
8. Bilgel, M. & Jedynek, B. M. Predicting time to dementia using a quantitative template of disease progression. *Alzheimers Dement. Diagn. Assess. Dis. Monit.* **11**, 205–215 (2019).
9. Young, A. L. *et al.* Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nat. Commun.* **9**, 4273 (2018).
10. Archetti, D. *et al.* Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. *NeuroImage Clin.* **24**, 101954 (2019).
11. Khanna, S. *et al.* Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer's Disease and Reconstruction of Relevant Biological Mechanisms. *Sci. Rep.* **8**, 11173 (2018).
12. Lorenzi, M., Filippone, M., Frisoni, G. B., Alexander, D. C. & Ourselin, S. Probabilistic disease progression modeling to characterize diagnostic uncertainty: Application to staging and prediction in Alzheimer's disease. *NeuroImage* **190**, 56–68 (2019).
13. van Maurik, I. S. *et al.* Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurol.* **18**, 1034–1044 (2019).
14. Birkenbihl, C., Salimi, Y., Fröhlich, H., Japanese Alzheimer's Disease Neuroimaging Initiative, &

- Alzheimer's Disease Neuroimaging Initiative. Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling. *Alzheimers Dement. J. Alzheimers Assoc.* (2021) doi:10.1002/alz.12387.
15. Oxtoby, N. P. *et al.* Targeted screening for Alzheimer's disease clinical trials using data-driven disease progression models. *medRxiv* 2021.01.29.21250773 (2021) doi:10.1101/2021.01.29.21250773.
  16. Insel, P. S. *et al.* Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. *Ann. Clin. Transl. Neurol.* **2**, 534–547 (2015).
  17. Kühnel, L. *et al.* Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study. *Alzheimers Dement. J. Alzheimers Assoc.* (2021) doi:10.1002/alz.12363.
  18. Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. *U.S. Food and Drug Administration* <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products> (2019).
  19. Burns, D. K. *et al.* The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. *Alzheimers Dement. Transl. Res. Clin. Interv.* **5**, 661–670 (2019).
  20. Burns, D. K. *et al.* Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* **20**, 537–547 (2021).
  21. Schiratti, J.-B., Allasonniere, S., Colliot, O. & Durrleman, S. Learning spatiotemporal trajectories from manifold-valued longitudinal data. in *Neural Information Processing Systems* (2015).
  22. Schiratti, J.-B., Allasonnière, S., Colliot, O. & Durrleman, S. A Bayesian Mixed-Effects Model to Learn Trajectories of Changes from Repeated Manifold-Valued Observations. *J. Mach. Learn. Res.* **18**, 1–33 (2017).
  23. Marinescu, R. V. *et al.* TADPOLE Challenge: Accurate Alzheimer's Disease Prediction Through Crowdsourced Forecasting of Future Data. in *Predictive Intelligence in Medicine* (eds. Rekik, I., Adeli, E. & Park, S. H.) vol. 11843 1–10 (Springer International Publishing, 2019).
  24. Nguyen, M. *et al.* Predicting Alzheimer's disease progression using deep recurrent neural networks. *NeuroImage* **222**, 117203 (2020).
  25. Mueller, S. G. *et al.* Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Alzheimers Dement. J. Alzheimers Assoc.* **1**, 55–66 (2005).
  26. Jack, C. R. *et al.* The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J. Magn. Reson. Imaging JMRI* **27**, 685–691 (2008).
  27. Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* **74**, 201–209 (2010).
  28. Jack, C. R. *et al.* Update on the MRI Core of the Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement. J. Alzheimers Assoc.* **6**, 212–220 (2010).
  29. Beckett, L. A. *et al.* The Alzheimer's Disease Neuroimaging Initiative 2: Increasing the Length, Breadth, and Depth of our Understanding. *Alzheimers Dement. J. Alzheimers Assoc.* **11**, 823–831 (2015).
  30. Jack, C. R. *et al.* Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

- Alzheimers Dement.* **11**, 740–756 (2015).
31. Weiner, M. W. *et al.* The Alzheimer’s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. *Alzheimers Dement. J. Alzheimers Assoc.* **13**, 561–571 (2017).
  32. Ellis, K. A. *et al.* The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. *Int. Psychogeriatr.* **21**, 672–687 (2009).
  33. Albrecht, M. A. *et al.* Longitudinal cognitive decline in the AIBL cohort: The role of APOE  $\epsilon$ 4 status. *Neuropsychologia* **75**, 411–419 (2015).
  34. Iwatsubo, T. Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and future. *Alzheimers Dement.* **6**, 297–299 (2010).
  35. Iwatsubo, T. *et al.* Japanese and North American Alzheimer’s Disease Neuroimaging Initiative studies: Harmonization for international trials. *Alzheimers Dement.* **14**, 1077–1087 (2018).
  36. Galluzzi, S. *et al.* Clinical and biomarker profiling of prodromal Alzheimer’s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’. *J. Intern. Med.* **279**, 576–591 (2016).
  37. Albani, D. *et al.* Plasma A $\beta$ 42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. *J. Alzheimers Dis. JAD* **69**, 37–48 (2019).
  38. Dufouil, C. *et al.* Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. *Alzheimers Res. Ther.* **9**, (2017).
  39. Folstein, M. F., Folstein, S. E. & McHugh, P. R. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* **12**, 189–198 (1975).
  40. Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer’s disease. *Am. J. Psychiatry* **141**, 1356–1364 (1984).
  41. O’Bryant, S. E. *et al.* Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores. *Arch. Neurol.* **65**, 1091–1095 (2008).
  42. Hedges, E. P. *et al.* Reliability of structural MRI measurements: The effects of scan session, head tilt, inter-scan interval, acquisition sequence, FreeSurfer version and processing stream. *NeuroImage* 118751 (2021) doi:10.1016/j.neuroimage.2021.118751.
  43. Blennow, K. *et al.* Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. *Alzheimers Dement.* **11**, 58–69 (2015).
  44. Cullen, N. C. *et al.* Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. *Nat. Aging* **1**, 114–123 (2021).
  45. Chen, R. *et al.* Developing Measures of Cognitive Impairment in the Real World from Consumer-Grade Multimodal Sensor Streams. in *Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining* 2145–2155 (Association for Computing Machinery, 2019). doi:10.1145/3292500.3330690.
  46. Mohs, R. C. *et al.* Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. *Alzheimer Dis. Assoc. Disord.* **11 Suppl 2**, S13-21 (1997).

47. Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. & Martin, R. L. A new clinical scale for the staging of dementia. *Br. J. Psychiatry* **140**, 566–572 (1982).
48. Jovicich, J. *et al.* Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. *NeuroImage* **30**, 436–443 (2006).
49. Sled, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE Trans. Med. Imaging* **17**, 87–97 (1998).
50. Boyes, R. G. *et al.* Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. *NeuroImage* **39**, 1752–1762 (2008).
51. Chow, N. *et al.* Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimer’s Disease Neuroimaging Initiative. *Am. J. Neuroradiol.* **36**, 653–660 (2015).
52. Fujishima, M. *et al.* Sample Size Estimation for Alzheimer’s Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. *J. Alzheimers Dis. JAD* **56**, 75–88 (2017).
53. Operto, G. *et al.* CATI: A Large Distributed Infrastructure for the Neuroimaging of Cohorts. *Neuroinformatics* **14**, 253–264 (2016).
54. Routier, A. *et al.* Clinica: An Open-Source Software Platform for Reproducible Clinical Neuroscience Studies. *Front. Neuroinformatics* **15**, 39 (2021).
55. Mulder, E. R. *et al.* Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. *NeuroImage* **92**, 169–181 (2014).
56. Marizzoni, M. *et al.* Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. *Hum. Brain Mapp.* **36**, 3516–3527 (2015).
57. Landau, S. M. *et al.* Measurement of longitudinal  $\beta$ -amyloid change with 18F-florbetapir PET and standardized uptake value ratios. *J. Nucl. Med. Off. Publ. Soc. Nucl. Med.* **56**, 567–574 (2015).
58. Landau, S., Murphy, A., Qie Lee, J., Ward, T. & Jagust, W. Florbetapir (AV45) processing methods. (2021).
59. Landau, S., Murphy, A., Qie Lee, J., Ward, T. & Jagust, W. Florbetaben (FBB) processing methods. (2021).
60. Klunk, W. E. *et al.* The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement. J. Alzheimers Assoc.* **11**, 1-15.e1–4 (2015).
61. Royse, S. K. *et al.* Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. *Alzheimers Res. Ther.* **13**, 99 (2021).
62. Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol. (Berl.)* **82**, 239–259 (1991).
63. Landau, S., Ward, T. J., Murphy, A. & Jagust, W. Flortaucipir (AV-1451) processing methods. (2021).
64. Jack, C. R. *et al.* A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology* **87**, 539–547 (2016).
65. Jack, C. R. *et al.* NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. *Alzheimers Dement.* **14**, 535–562 (2018).
66. Nguyen, M., Sun, N., Alexander, D. C., Feng, J. & Yeo, B. T. T. Modeling Alzheimer’s disease progression using deep recurrent neural networks. in *2018 International Workshop on Pattern Recognition in*

*Neuroimaging (PRNI)* 1–4 (2018). doi:10.1109/PRNI.2018.8423955.

67. Inference for the Random Effects. in *Linear Mixed Models for Longitudinal Data* (eds. Verbeke, G. & Molenberghs, G.) 77–92 (Springer, 2000). doi:10.1007/978-0-387-22775-7\_7.

68. Maheux, E. Forecasting individual progression trajectories in Alzheimer’s disease – software and source data. (2022) doi:10.5281/zenodo.7331109.

69. Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with Python. in 92–96 (2010). doi:10.25080/Majora-92bf1922-011.

## ACKNOWLEDGMENTS

EM, IK, JO, SE and SD received funding from the European Research Council (ERC) under grant agreement No. 678304, the Agence Nationale de la Recherche (ANR) under the “Investissements d’avenir” program, grants ANR-10-IAIHU-06 (IHU ICM) and ANR-19-P3IA-0001 (PRAIRIE 3IA Institute). EM, IK, JO, CB, MHA and SD received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 826421 (TVB-Cloud). DA and SD received funding from the joint program in neurodegenerative diseases (JPND) under grant agreement ANR-19-JPW2-000 (E-DADS). SE received funding via an APHP-Inria collaboration grant (poste d’accueil) within the ARAMIS project-team.

The data used in the preparation of this article were obtained from:

- The Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu),
- The Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL),
- The Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI),
- The PharmaCog Consortium,
- The MEMENTO cohort.

The investigators of these studies contributed to the design and implementation of the corresponding cohorts, provided data, but did not participate in analysis or writing of this report. Complete listings of these investigators can be found at:

- ADNI: [https://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)
- AIBL: <https://aibl.csiro.au/about/aibl-research-team/>
- J-ADNI: <https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors>
- PharmaCog: [https://neugrid2.eu/wp-content/uploads/2022/01/pharmacog\\_investigators\\_list.pdf](https://neugrid2.eu/wp-content/uploads/2022/01/pharmacog_investigators_list.pdf),
- MEMENTO: supplementary material.

Data collection and sharing was partly funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La

Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.

AIBL core funding was provided by the Commonwealth Scientific and Industrial Research Organisation (CSIRO). The cohort was also supported by the University of Melbourne, Neurosciences Australia Ltd, Edith Cowan University, Mental Health Research Institute, Alzheimer's Australia, National Ageing Research Institute, Austin Health, University of WA, CogState Ltd., Macquarie University, Hollywood Private Hospital, Sir Charles Gairdner Hospital.

J-ADNI was supported by the following grants: Translational Research Promotion Project from the New Energy and Industrial Technology Development Organization of Japan; Research on Dementia, Health Labor Sciences Research Grant; Life Science Database Integration Project of Japan Science and Technology Agency; Research Association of Biotechnology (contributed by Astellas Pharma Inc., Bristol-Myers Squibb, Daiichi-Sankyo, Eisai, Eli Lilly and Company, Merck-Banyu, Mitsubishi Tanabe Pharma, Pfizer Inc., Shionogi & Co., Ltd., Sumitomo Dainippon, and Takeda Pharmaceutical Company), Japan, and a grant from an anonymous foundation.

The IMI-PharmaCog/E-ADNI project was funded by the European seventh framework program and European Federation of Pharmaceutical Industries and Associations (EFPIA) for the Innovative Medicine Initiative (Grant no. 115009; <http://www.pharmacog.org>).

The MEMENTO cohort was funded through research grants from the Fondation Plan Alzheimer (Alzheimer Plan 2008–2012), the French Ministry of Higher Education, Research and Innovation (Plan Maladies Neurodégénératives 2014-2019). This work was also supported by CIC1401-EC, Bordeaux University Hospital (CHU Bordeaux, sponsor of the cohort), Inserm, and the University of Bordeaux. The MEMENTO cohort has received funding from AVID, GE Healthcare and FUJIREBIO through private-public partnerships. This work was undertaken with resources from the Dementias Platform UK (DPUK) Data Portal; the Medical Research Council supports DPUK through grant MR/L023784/2.

## **AUTHOR CONTRIBUTIONS**

SE, CD, MH-A, and SD conceived and supervised the research. EM, IK, JO, CB, DA, VB conducted the research and performed data analysis. All authors contributed to writing the paper and agreed on its content.

Editorial support, in the form of medical writing and copyediting, was provided by Julie Sappa of Alex Edelman and Associates.

## **COMPETING INTERESTS**

SE received personal fees from Biogen, Eisai, Roche, and GE Healthcare for presentations and participation in advisory boards. SD is co-inventor of the patent “a method for determining the temporal progression of a biological phenomenon and associated methods and devices” which protects the potential uses of AD Course Map including targeting the time to administer medicine, or identifying a biomarker (applicants: Inserm, CNRS, Sorbonne Université, Inria, Ecole Polytechnique, ICM, AP-HP, inventors: Stanley Durrleman, Jean-Baptiste Schiratti, Stéphanie Allasonnière, Olivier Colliot, international application number: PCT/IB2016/052699, granted in the USA (grant number 10832089), published in Europe and Japan. The remaining authors declare no competing interests.

## **TABLES**



	<b>ADNI</b>	<b>AIBL</b>	<b>PHARMACOG</b>	<b>J-ADNI</b>	<b>MEMENTO</b>
<i>Number of subjects</i>	1,652	460	111	470	1,994
<i>Number of visits</i>	6.1 ± 3.0 [2, 17]	3.7 ± 0.7 [2, 4]	5.1 ± 0.6 [3, 7]	5.1 ± 0.8 [4, 6]	6.9 ± 1.8 [2, 9]
<i>Follow-up duration (y)</i>	4.8 ± 3.1 [1.4, 15.2]	4.1 ± 1.0 [1.5, 4.5]	2.0 ± 0.3 [1.5, 3.0]	2.7 ± 0.5 [1.5, 3.0]	3.8 ± 0.7 [1.4, 5.2]
<i>Time between visits (m)</i>	11.3 ± 6.6 [1.8, 62.8]	18.2 ± 2.0 [18.0, 54.0]	6.0 ± 0.6 [6.0, 18.0]	7.8 ± 2.8 [6.0, 24.0]	7.7 ± 3.4 [1.5, 53.7]
<i>Age at baseline (y)</i>	73.3 ± 7.0 [55.1, 91.5]	71.5 ± 7.1 [55.3, 92.1]	69.8 ± 7.4 [50.5, 84.5]	71.8 ± 6.7 [30.0, 85.0]	70.6 ± 8.6 [32.5, 92.6]
<i>Female</i>	771 (46.7 %)	247 (53.7 %)	63 (56.8 %)	247 (52.6 %)	1215 (60.9 %)
<b>Education level</b>					
<i>≤ 9 years</i>	24 (1.5 %)	75 (16.3 %)	47 (42.3 %)	64 (13.6 %)	355 (17.8 %)
<i>Between 10 and 15 years</i>	525 (31.8 %)	278 (60.4 %)	39 (35.1 %)	255 (54.3 %)	1016 (51.0 %)
<i>≥ 16 years</i>	1103 (66.8 %)	107 (23.3 %)	25 (22.5 %)	151 (32.1 %)	571 (28.6 %)
<i>Missing</i>					52 (2.6 %)
<b>APOE-ε4 copies</b>					
<i>0</i>	917 (55.5 %)	295 (64.1 %)	56 (50.5 %)	251 (53.4 %)	1340 (67.2 %)
<i>1</i>	588 (35.6 %)	138 (30.0 %)	41 (36.9 %)	176 (37.4 %)	500 (25.1 %)
<i>2</i>	144 (8.7 %)	27 (5.9 %)	10 (9.0 %)	40 (8.5 %)	66 (3.3 %)
<i>Missing</i>	3 (0.2 %)		4 (3.6 %)	3 (0.6 %)	88 (4.4 %)
<b>Diagnosis at baseline</b>					
<i>CU</i>	649 (39.3 %)	365 (79.3 %)		140 (29.8 %)	831 (41.7 %)
<i>MCI</i>	803 (48.6 %)	59 (12.8 %)	111 (100.0 %)	211 (44.9 %)	1163 (58.3 %)
<i>Dementia</i>	200 (12.1 %)	36 (7.8 %)		119 (25.3 %)	
<b>A/T/N/C profile (worst for all visits)</b>					
<i>A-T-N-C-</i>	133 (8.1 %)	91 (19.8 %)		24 (5.1 %)	104 (5.2 %)
<i>A*T*N*C-</i>	45 (2.7 %)	122 (26.5 %)		82 (17.4 %)	129 (6.5 %)
<i>A+T-N-C-</i>	80 (4.8 %)	48 (10.4 %)		6 (1.3 %)	26 (1.3 %)
<i>A+T+N-C-</i>	27 (1.6 %)	4 (0.9 %)		1 (0.2 %)	2 (0.1 %)
<i>A+T+N+C-</i>	47 (2.8 %)	11 (2.4 %)		1 (0.2 %)	24 (1.2 %)
<i>A*T*N*C~</i>	80 (4.8 %)	52 (11.3 %)	2 (1.8 %)	95 (20.2 %)	880 (44.1 %)
<i>A+T+N+C~</i>	191 (11.6 %)	6 (1.3 %)	35 (31.5 %)	28 (6.0 %)	109 (5.5 %)
<i>A*T*N*C+</i>	111 (6.7 %)	49 (10.7 %)		124 (26.4 %)	118 (5.9 %)

<i>A+T+N+C+</i>	300 (18.2 %)	10 (2.2 %)	5 (4.5 %)	45 (9.6 %)	40 (2.0 %)
<i>A+[T- or N-]</i>	221 (13.4 %)	13 (2.8 %)	28 (25.2 %)	15 (3.2 %)	84 (4.2 %)
<i>C[~ or +]</i>					
<i>A-T+ *</i>	183 (11.1 %)	26 (5.7 %)	8 (7.2 %)	10 (2.1 %)	56 (2.8 %)
<i>A-T-N+C-</i>	40 (2.4 %)	13 (2.8 %)		12 (2.6 %)	81 (4.1 %)
<i>A-T*N*</i>	194 (11.7 %)	15 (3.3 %)	33 (29.7 %)	27 (5.7 %)	341 (17.1 %)
<i>C[~ or +]</i>					

Table 1 – Characteristics of study participants. Format for continuous variables: mean  $\pm$  standard deviation [lowest, highest]. Stars in A(myloid)/T(au)/N(eurodegeneration)/C(linical) classification indicate unknown status (see Methods for details). (y) years, (m) months, APOE: Apolipoprotein E, CU: cognitively unimpaired (CDR=0 for MEMENTO), MCI: mild cognitive impairment (CDR=0.5 for MEMENTO), CDR: Clinical Dementia Rating.

	<b>ADNI</b>	<b>AIBL</b>	<b>PHARMACOG</b>	<b>J-ADNI</b>	<b>MEMENTO</b>
<i>CDR</i>	0.4 $\pm$ 0.5	0.2 $\pm$ 0.4	0.5 $\pm$ 0.1	0.5 $\pm$ 0.4	0.3 $\pm$ 0.3
<i>(global)</i>	[0.0, 3.0] (96.6 %)	[0.0, 3.0] (99.6 %)	[0.0, 1.0] (88.4 %)	[0.0, 3.0] (99.8 %)	[0.0, 3.0] (96.9 %)
<i>CDR</i>	2.0 $\pm$ 2.8	0.9 $\pm$ 2.5		2.5 $\pm$ 2.6	0.8 $\pm$ 1.6
<i>(sum of boxes)</i>	[0.0, 18.0] (96.6 %)	[0.0, 18.0] (99.6 %)	/	[0.0, 18.0] (99.8 %)	[0.0, 18.0] (96.4 %)
<i>MMSE</i>	26.9 $\pm$ 3.9	27.5 $\pm$ 4.1	26.2 $\pm$ 2.7	25.2 $\pm$ 4.1	27.8 $\pm$ 2.7
	[0.0, 30.0] (94.9 %)	[0.0, 30.0] (99.8 %)	[10.0, 30.0]	[1.0, 30.0] (99.8 %)	[2.0, 30.0] (97.9 %)
<i>ADAS-Cog13</i>	16.4 $\pm$ 11.5		20.4 $\pm$ 7.7	19.8 $\pm$ 11.3	
	[0.0, 85.0] (94.3 %)	/	[2.7, 50.3] (97.1 %)	[0.0, 68.0] (99.5 %)	/
<i>Lateral ventricles volume (% ICV)</i>	2.63 $\pm$ 1.26	2.48 $\pm$ 1.30	2.58 $\pm$ 1.12	2.65 $\pm$ 1.19	2.25 $\pm$ 1.16
	[0.57, 8.64] (42.6 %)	[0.59, 7.44] (47.3 %)	[0.74, 6.75] (97.7 %)	[0.54, 9.79] (93.3 %)	[0.36, 9.32] (25.2 %)
<i>Hippocampus volume (% ICV)</i>	0.47 $\pm$ 0.07	0.47 $\pm$ 0.06	0.46 $\pm$ 0.10	0.42 $\pm$ 0.09	0.48 $\pm$ 0.08
	[0.23, 0.72] (42.6 %)	[0.26, 0.69] (47.4 %)	[0.17, 0.67] (97.7 %)	[0.16, 0.65] (93.3 %)	[0.19, 0.87] (25.2 %)
<i>Abeta<sub>1-42</sub> level in CSF (\$)</i>	-0.35 $\pm$ 1.16	0.61 $\pm$ 1.15	-0.53 $\pm$ 1.17	-0.23 $\pm$ 1.25	-0.14 $\pm$ 1.10
	[-1.97, 6.56] (25.6 %)	[-1.51, 3.56] (7.1 %)	[-2.68, 2.53] (19.4 %)	[-2.57, 3.09] (12.7 %)	[-2.11, 3.16] (3.6 %)
<i>p-Tau<sub>181</sub> level in CSF (\$)</i>	0.22 $\pm$ 1.03	-0.34 $\pm$ 0.81	0.07 $\pm$ 1.02	0.13 $\pm$ 1.16	0.02 $\pm$ 1.04
	[-1.19, 7.07]	[-1.96, 2.15]	[-1.13, 4.59]	[-1.62, 4.04]	[-1.66, 6.74]

	(25.6 %)	(7.1 %)	(19.4 %)	(12.7 %)	(3.6 %)
<i>Total Tau</i>	0.23 ± 1.02	-0.89 ± 0.93	0.07 ± 0.91		-0.03 ± 1.07
<i>level in</i>	[-1.44, 6.19]	[-1.89, 6.77]	[-1.02, 4.44]	/	[-1.17, 5.97]
<i>CSF (§)</i>	(25.6 %)	(7.1 %)	(19.4 %)		(3.6 %)
<i>Amyloid PET</i>	36.6 ± 44.4				
<i>(CL)</i>	[-33.6, 213.2]	/(*)	/	/	/(*)
	(28.2 %)				
<i>Tau PET</i>	1.58 ± 0.31				
<i>(SUVR)</i>	[1.14, 4.64]	/	/	/	/
	(9.0 %)				

Table 2 – Distribution of endpoints for study participants. Data is reported as mean value ± standard deviation [lowest, highest] (% available data when some data is missing), or “/” if variable is not available at all. CDR: Clinical Dementia Rating, MMSE: Mini Mental State Examination, ADAS-Cog13: Alzheimer’s Disease Assessment Scale – cognitive sub-scale (13 items), ICV: Intracranial volume, CSF: Cerebrospinal fluid, (§) in harmonized units (see Methods), PET: Positron emission tomography, CL: Centiloid Scale, (\*) Amyloid PET data for the AIBL and MEMENTO cohorts were used only for the determination of the amyloid status, SUVR: Standardized Uptake Value Ratio.

<b>Clinical trial description</b>	<b>Inclusion/exclusion criteria</b>	<b>Primary outcome (annual rate of change of ...)</b>	<b>Trial duration window</b>	<b>Inspiration from existing AD trial (ClinicalTrials.gov identifier)</b>
<i>Participants at risk of AD onset</i>	- Age [59.9, 76.1] - CDR global = 0 - MMSE ≥ 24 - 1 risk factor of: > Homozygous APOE-ε4 > Heterozygous APOE-ε4 & Amyloid + (*)	MMSE	4 years ± 12 months	Novartis Generation S2 (NCT03131453)
<i>Preclinical AD with high brain amyloid levels</i>	- Age [54.9, 81.1] - CDR global = 0 - MMSE ≥ 27 - Amyloid + (*)	ADAS-Cog13	4 years ± 12 months	Eisai AHEAD A45 (NCT04468659)
<i>Early AD with high brain amyloid levels</i>	- Age [49.9, 86.1] - CDR global = 0.5 - MMSE ≥ 24 - Amyloid + (*)	- MMSE - CDR-SB	1.5 years ± 6 months	Biogen EMERGE / ENGAGE (NCT02477800 & NCT02484547)
<i>Early AD with high brain tau levels</i>	- Age [54.9, 81.1] - CDR global = 0.5 - p-Tau + (*)	ADAS-Cog13	4.5 years ± 6 months	Janssen Autonomy (NCT04619420)
<i>MCI probably due to AD or mild AD</i>	- Age [54.9, 86.1] - CDR global = 0.5 or 1 - From AD datasets	MMSE	3 years ± 9 months	/
	* CSF or PET (worst visit to date)			

Table 3 – Description of the simulated trials. Six trials were simulated because we considered two possible primary outcomes for the trial targeting early Alzheimer’s disease (AD) with high brain amyloid levels (third row). MCI: mild cognitive impairment, AD: Alzheimer’s disease.

## FIGURES




Figure 1 – Disease progression models forecast the progression of endpoints from historical data of a participant. In this simplified example, the model has only 3 endpoints (Amyloid PET, Hippocampus volume and mini-mental state examination (MMSE)). The participant has been observed twice at 70 and 71 years old (colored crosses). After normalizing the data to a 0-1 scale (0 being the most normal and 1 the maximum pathological change), the model predicts the participant-specific progression curves. From these curves, one forecasts the values of the three endpoints in 4 years' time (colored dots). As shown in this example, AD Course Map does not require imputation of missing data. In trial simulations, the curves are predicted from the data at a single time-point, e.g. the baseline. CL: Centiloid Scale, ICV: Intracranial volume.




Figure 2 – AD Course Map forecasts cognitive decline better than alternative methods. The mean absolute error is reported for the reference participant: a 75-year-old American woman from ADNI with an average level of education, no APOE- $\epsilon$ 4 mutation and a A+T+N+C~ status (i.e. with CDR global of 0.5), for whom we forecast neuropsychological assessments in three years' time, based on two past visits separated by eight months and for which all data were available. Box plots represent median value, first and third quartiles; whiskers represent the empirical 95% confidence interval. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file. MAE: mean absolute error.




Figure 3 – Changes in forecast absolute errors depending on covariates. Results are presented for the forecast of ADAS-Cog13 with the AD Course Map. Panel a: changes due to forecast design (4 top rows, in brown), genetic and sociodemographic characteristics of the participant (rows 5 to 10, in blue), the cohort of the participant (rows 11 and 12, in pink), and missing data (rows 13 to 16, in gray). Panel b: changes due to A(myloid)/T(au)/N(eurodegeneration)/C(linical) status of the participant, grouped in: Alzheimer’s continuum at the top (8 top rows, in green), possible Alzheimer’s disease and concomitant non-Alzheimer’s pathologic change in between (row 9, in orange), and suspected non-Alzheimer’s pathophysiology (SNAP) at the bottom (3 bottom rows, in gray). Coefficients below zero indicate a lower mean absolute error (MAE) (better forecast) than those for the reference participant and design. For example, if the reference participant comes from J-ADNI instead of ADNI, the prediction of ADAS-Cog13 is more accurate, resulting in a 0.63 point decrease in MAE (95% CI=[0.32, 0.96]). Box plots represent median value, first and third quartiles; whiskers represent the empirical 95% confidence interval. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file. MAE: mean absolute error.




Figure 4 – Illustration of the prognostic enrichment procedure in a clinical trial. Participants are selected first using standard inclusion criteria and undergo a series of exams. A disease progression model, such as AD Course Map, then forecasts the progression of each participant’s data and predicts if the participant is likely to progress significantly during the trial, as measured by the predicted outcome change, which is the mini-mental state examination (MMSE) in this example. The treatment effect (e.g. a 25% reduction of the change of the MMSE during trial) leads to a greater effect size, and therefore a smaller sample size, on the group of predicted fast progressors compared to the group of predicted slow progressors or the two groups combined. As a result, one may demonstrate the treatment efficacy with fewer participants by monitoring only the group of predicted fast progressors.






Figure 5 – AD Course Map and RNN-AD select participants at risk of experiencing a worsening of the outcome during the trial. Receiver operating characteristic (ROC) curves are shown. They demonstrate the performance of AD Course Map and RNN-AD in selecting the group of participants with the largest change in primary outcome during follow-up. Shaded areas correspond to the empirical 95% confidence interval. The green circle and orange triangle on each curve correspond to selections splitting the participants in two equal groups, with

bars representing the 95% confidence intervals. The cross in gray gives the specificity and sensitivity when APOE-ε4 carriers (with 1 or 2 copies) are selected, with bars indicating the 95% confidence interval (note: the first trial includes only APOE-ε4 carriers, and there is, therefore, no gray cross). Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file. AUC: area under the ROC curve (mean ± standard deviation with 95% confidence interval).





Figure 6 – Enrichment based on AD Course Map significantly decreases the sample size for a hypothetical treatment effect ranging from 20% to 30%. Reported sample sizes are the total size for two arms. The light shaded areas represent the 95% confidence intervals and the dark shaded areas the 50% confidence interval around the median value. For all preclinical and early Alzheimer’s disease (AD) trials, enrichment based on AD Course Map significantly outperformed the enrichment based on APOE-ε4 carriership. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file.



# FORECASTING INDIVIDUAL PROGRESSION TRAJECTORIES IN ALZHEIMER'S DISEASE

Etienne Maheux, Igor Koval, Juliette Ortholand, Colin Birkenbihl, Damiano Archetti, Vincent Bouteloup, Stéphane Epelbaum, Carole Dufouil, Martin Hofmann-Apitius, Stanley Durrleman


## Supplementary information




**Supplementary Figure 1** Experimental protocol. Ten models were trained on 80% of the amyloid-positive participants from ADNI. Models were tested on hold-out amyloid positive ADNI participants, ADNI participants with unknown or negative amyloid status and participants from four external cohorts. For each test subject, a series of forecasts was made by partially blinding some of his visits. In this example, 10 forecasts are derived from a single participant having four visits. These predictions are split randomly into different sets, such that, in each set, the forecasts deriving from a given subject never share common visits. In this example, forecast 1 and 2 share a common visit: they are distributed in different sets, whereas forecasts 1 and 10 may be in the same set.



**Supplementary Figure 2** Forecast of mini-mental state examination (MMSE) with AD Course Map: changes in absolute errors due to covariates. Left panel: changes due to forecast design (4 top rows, in brown), genetic and sociodemographic characteristics of the participant (rows 5 to 10, in blue), the cohort of the participant (rows 11 to 14, in pink), and missing data (rows 15 to 18, in gray). Right panel: changes due to A(myloid)/T(au)/N(eurodegeneration)/C(linical) status of the participant, grouped in: Alzheimer’s continuum at the top (8 top rows, in green), possible Alzheimer’s disease and concomitant non-Alzheimer’s pathologic change in between (row 9, in orange), suspected non-Alzheimer’s pathophysiology (SNAP) at the bottom (3 bottom row, in gray). A positive difference in mean absolute error (MAE) means forecasts are less accurate than for the reference participant (A+T+N+C~) and design. Box plots represent median value, first and third quartiles; whiskers represent the empirical 95% confidence interval. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file. MAE: mean absolute error.



**Supplementary Figure 3** Forecast of the clinical dementia rating – sum of boxes (CDR-SB) with AD Course Map: changes in absolute errors due to covariates. Left panel: changes due to forecast design (4 top rows, in brown), genetic and sociodemographic characteristics of the participant (rows 5 to 10, in blue), the cohort of the participant (rows 11 to 13, in pink), and missing data (rows 14 to 17, in gray). Right panel, changes due to A(myloid)/T(au)/N(eurodegeneration)/C(linical) status of the participant, grouped in: Alzheimer’s continuum at the top (8 top rows, in green), possible Alzheimer’s disease and concomitant non-Alzheimer’s pathologic change in between (row 9, in orange), suspected non-Alzheimer’s pathophysiology (SNAP) at the bottom (3 bottom row, in gray). A positive difference in mean absolute error (MAE) means forecasts are less accurate than for the reference participant (A+T+N+C~) and design. Box plots represent median value, first and third quartiles; whiskers represent the empirical 95% confidence interval. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file. MAE: mean absolute error.



**Supplementary Figure 4** Analysis of the biases in the population selected by AD Course Map as likely to be progressors for the considered outcome. For each panel, the first 4 rows (in blue) correspond to genetic and sociodemographic characteristics of the participant; rows 5 to 8 (in gray) correspond to missing data, and the last 4 rows (in pink) correspond to the cohort of the participant. Box plots represent median value, first and third quartiles; whiskers represent the empirical 95% confidence interval. Statistics are computed for  $n=100$  resampling of the validation set (see Methods). Source data are provided as a Source Data file.

Feature	AD Course Map	RNN-AD
ADAS-Cog13	4.07 ± 0.20 [3.88, 4.35]	7.71 ± 0.72 [7.07, 8.28]
MMSE	1.71 ± 0.04 [1.67, 1.74]	3.15 ± 0.23 [2.91, 3.38]
CDR-SB	0.95 ± 0.11 [0.82, 1.07]	2.31 ± 0.23 [1.99, 2.57]
Lateral ventricles volume (% ICV)	0.16 ± 0.01 [0.14, 0.17]	0.66 ± 0.13 [0.56, 0.75]
Hippocampus volume (% ICV)	0.12 ± 0.00 [0.12, 0.12]	0.33 ± 0.04 [0.28, 0.37]
Abeta <sub>1-42</sub> level in CSF (§)	0.47 ± 0.02 [0.45, 0.49]	0.37 ± 0.08 [0.29, 0.48]
p-Tau <sub>181</sub> level in CSF (§)	0.69 ± 0.04 [0.65, 0.74]	0.51 ± 0.08 [0.43, 0.62]
PET Amyloid (CL)	8.13 ± 3.50 [5.46, 13.47]	22.67 ± 1.93 [20.54, 24.40]
PET Tau (SUVR)	0.24 ± 0.02 [0.22, 0.26]	0.29 ± 0.07 [0.21, 0.35]

**Supplementary Table 1** Goodness-of-fit of AD Course Map and RNN-AD. Root mean square errors between the predicted and observed endpoint in the training data set. Data is presented as mean ± standard deviation, with empirical 80% confidence interval on the n=10 models trained. Source data are provided as a Source Data file. ICV: Intracranial volume. (§) In harmonized units (see Methods). CL: Centiloid Scale. SUVR: Standard Uptake Value Ratio.

Endpoint	Models compared (left – right)		Mean difference in adjusted MAE	Mean difference in adjusted MAE (relative)	P-value (empirical for n=100 runs)
ADAS-Cog13	AD Course Map	RNN-AD	-0.55	-8.5%	0.07
		Linear mixed model	-1.87	-23.9%	< 0.01
		No-change prediction	-2.87	-32.5%	< 0.01
	RNN-AD	Linear mixed model	-1.32	-16.8%	< 0.01
		No-change prediction	-2.32	-26.2%	< 0.01
		Linear mixed model	-1.00	-11.3%	< 0.01
MMSE	AD Course Map	RNN-AD	-0.20	-7.4%	0.01
		Linear mixed model	-0.78	-23.4%	< 0.01
		No-change prediction	-0.99	-28.1%	< 0.01
	RNN-AD	Linear mixed model	-0.57	-17.2%	< 0.01
		No-change prediction	-0.79	-22.3%	< 0.01
		Linear mixed model	-0.22	-6.2%	< 0.01
CDR-SB	AD Course Map	RNN-AD	-0.10	-4.9%	0.12
		Linear mixed model	-0.50	-21.1%	< 0.01
		No-change prediction	-0.67	-26.6%	< 0.01
	RNN-AD	Linear mixed model	-0.40	-17.0%	< 0.01
		No-change prediction	-0.58	-22.8%	< 0.01
		Linear mixed model	-0.18	-7.0%	< 0.01

**Supplementary Table 2** Comparison of forecast errors across models. The adjusted mean absolute error (MAE) is compared for all model pairs. AD Course Map significantly outperforms all alternative forecasting methods but RNN-AD for CDR-SB and ADAS-Cog13. Statistics are computed for n=100 resampling of the validation set (see Methods). P-value is calculated from the empirical distribution of adjusted MAE paired differences (non-parametric two-sided test, p-values under 0.01 could not be estimated); no multiple comparison adjustment is performed. Source data are provided as a Source Data file (same data as for the Figure 2).



Trial	RNN-AD	AD Course Map
Participants at risk of AD onset (MMSE)	29.3 ± 8.3 [11.5, 41.6]	37.8 ± 7.0 [21.2, 48.1]
Preclinical AD with high brain amyloid levels (ADAS-Cog13)	12.8 ± 3.1 [7.0, 18.7]	27.7 ± 3.5 [20.8, 34.7]
Early AD with high brain amyloid levels (CDR-SB)	34.0 ± 1.3 [31.9, 36.8]	35.0 ± 1.2 [33.1, 36.9]
Early AD with high brain amyloid levels (MMSE)	36.2 ± 1.3 [34.2, 39.1]	38.9 ± 1.4 [36.5, 41.9]
Early AD with high brain tau levels (ADAS-Cog13)	34.9 ± 3.2 [29.5, 41.4]	47.2 ± 2.7 [42.1, 51.7]
MCI probably due to AD or mild AD (MMSE)	32.0 ± 1.0 [30.4, 34.1]	44.4 ± 0.8 [42.7, 46.0]

**Supplementary Table 3** Pearson correlations (in %) between true outcome and prognosis score, for each simulated trial. Prognosis scores derived from AD Course Map always outperform the ones derived from RNN-AD. Data are presented as mean value ± standard deviation, with empirical 95% confidence interval. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file.

Trial	Target	Prevalence (%)	Selection	Selected (%)	Sensitivity (%)	Specificity (%)	Balanced Accuracy (%)	Precision (%)	NPV (%)	LR+	LR-	DOR
Participants at risk of AD onset (MMSE)	Patients with MMSE change greater than 0 pt in 4 years	67.5 ± 2.3 [63.0, 71.9]	AD Course Map	50.3 ± 2.3 [45.8, 55.0]	65.3 ± 3.2 [59.2, 71.8]	80.9 ± 3.6 [74.6, 87.5]	73.1 ± 2.7 [68.1, 77.7]	87.7 ± 2.4 [83.7, 92.0]	52.9 ± 4.1 [44.7, 61.5]	3.57 ± 0.80 [2.41, 5.17]	0.43 ± 0.05 [0.34, 0.52]	8.55 ± 2.66 [4.66, 14.73]
			RNN-AD	50.6 ± 2.7 [45.2, 56.3]	66.0 ± 3.1 [60.5, 71.9]	81.4 ± 4.2 [73.8, 89.5]	73.7 ± 2.7 [68.7, 79.4]	88.1 ± 2.8 [82.8, 93.6]	53.6 ± 3.7 [46.8, 59.4]	3.78 ± 1.02 [2.43, 6.43]	0.42 ± 0.05 [0.33, 0.51]	9.32 ± 3.37 [5.00, 18.39]
Preclinical AD with high brain amyloid levels (ADAS-Cog13)	Patients with ADAS-Cog13 change greater than 1.9 pts in 4 years	49.8 ± 1.5 [47.3, 52.9]	APOE-ε4 carriers	41.4 ± 0.8 [40.3, 43.0]	45.6 ± 1.7 [42.0, 49.0]	62.7 ± 1.9 [59.3, 66.1]	54.2 ± 1.6 [51.4, 57.4]	54.8 ± 2.3 [50.3, 59.0]	53.8 ± 2.2 [49.6, 57.6]	1.23 ± 0.10 [1.07, 1.43]	0.87 ± 0.05 [0.78, 0.95]	1.43 ± 0.19 [1.12, 1.84]
			AD Course Map	49.4 ± 1.5 [45.7, 52.3]	58.6 ± 2.3 [54.4, 62.4]	59.7 ± 2.2 [55.5, 64.0]	59.1 ± 1.6 [55.8, 62.1]	59.1 ± 2.1 [54.8, 63.5]	59.2 ± 2.2 [55.3, 63.1]	1.46 ± 0.10 [1.26, 1.64]	0.69 ± 0.05 [0.61, 0.79]	2.12 ± 0.28 [1.59, 2.68]
			RNN-AD	49.9 ± 1.5 [47.2, 53.4]	53.0 ± 2.2 [49.1, 57.2]	53.3 ± 2.6 [48.1, 57.7]	53.2 ± 1.9 [49.2, 56.4]	53.0 ± 2.8 [47.6, 58.9]	53.3 ± 2.0 [49.5, 57.3]	1.14 ± 0.09 [0.97, 1.31]	0.88 ± 0.07 [0.78, 1.03]	1.30 ± 0.20 [0.94, 1.67]
Early AD with high brain amyloid levels (CDR-SB)	Patients with CDR-SB change greater than 0.5 pt in 1.5 years	51.5 ± 0.8 [50.3, 53.0]	APOE-ε4 carriers	62.2 ± 0.4 [61.5, 63.0]	66.7 ± 0.7 [65.5, 68.2]	42.7 ± 0.9 [40.9, 44.1]	54.7 ± 0.7 [53.3, 55.9]	55.3 ± 1.0 [53.7, 57.3]	54.7 ± 1.1 [52.7, 57.0]	1.16 ± 0.03 [1.11, 1.21]	0.78 ± 0.03 [0.73, 0.84]	1.50 ± 0.09 [1.33, 1.65]
			AD Course Map	52.3 ± 0.6 [51.4, 53.5]	66.2 ± 1.0 [64.7, 68.0]	62.4 ± 1.0 [60.5, 64.4]	64.3 ± 0.8 [62.8, 65.9]	65.1 ± 1.0 [63.0, 67.1]	63.5 ± 1.2 [61.3, 65.8]	1.76 ± 0.06 [1.66, 1.87]	0.54 ± 0.02 [0.51, 0.58]	3.26 ± 0.22 [2.85, 3.73]
			RNN-AD	50.7 ± 0.6 [49.5, 51.9]	64.8 ± 1.0 [62.7, 66.6]	64.2 ± 1.2 [61.7, 66.4]	64.5 ± 0.9 [62.8, 66.1]	65.8 ± 1.2 [63.4, 67.8]	63.2 ± 1.2 [60.9, 65.4]	1.81 ± 0.07 [1.68, 1.94]	0.55 ± 0.02 [0.51, 0.59]	3.32 ± 0.26 [2.86, 3.79]
Early AD with high brain amyloid levels (MMSE)	Patients with MMSE change greater than 1.1 pts in 1.5 years	49.6 ± 0.7 [48.2, 50.8]	APOE-ε4 carriers	62.4 ± 0.4 [61.8, 63.2]	64.7 ± 0.9 [62.9, 66.6]	39.9 ± 0.9 [38.2, 41.4]	52.3 ± 0.8 [50.7, 53.9]	51.4 ± 0.9 [49.9, 53.3]	53.5 ± 1.3 [50.9, 55.9]	1.08 ± 0.03 [1.02, 1.13]	0.89 ± 0.04 [0.81, 0.96]	1.22 ± 0.08 [1.06, 1.40]
			AD Course Map	49.6 ± 0.6 [48.7, 50.6]	63.6 ± 0.9 [62.0, 65.2]	64.1 ± 1.0 [62.4, 66.0]	63.8 ± 0.7 [62.4, 65.0]	63.5 ± 1.0 [61.4, 65.3]	64.2 ± 1.0 [62.5, 66.2]	1.77 ± 0.06 [1.67, 1.88]	0.57 ± 0.02 [0.54, 0.60]	3.12 ± 0.20 [2.76, 3.46]
			RNN-AD	50.6 ± 0.7 [49.2, 52.0]	63.2 ± 1.0 [61.1, 65.1]	61.7 ± 1.1 [59.3, 63.4]	62.4 ± 0.8 [60.7, 63.8]	61.8 ± 1.1 [59.6, 63.8]	63.1 ± 1.1 [61.2, 65.5]	1.65 ± 0.06 [1.52, 1.75]	0.60 ± 0.02 [0.56, 0.64]	2.77 ± 0.19 [2.39, 3.10]
Early AD with high brain tau levels (ADAS-Cog13)	Patients with ADAS-Cog13 change greater than 6.1 pts in 4.5 years	50.2 ± 2.0 [46.5, 53.7]	APOE-ε4 carriers	57.7 ± 1.9 [54.5, 61.7]	70.1 ± 2.6 [65.4, 74.6]	54.7 ± 2.3 [50.4, 58.8]	62.4 ± 1.7 [59.0, 65.5]	60.9 ± 2.6 [55.5, 65.5]	64.5 ± 2.5 [60.3, 69.5]	1.55 ± 0.10 [1.37, 1.74]	0.55 ± 0.05 [0.46, 0.64]	2.88 ± 0.43 [2.12, 3.70]
			AD Course Map	49.3 ± 2.0 [45.1, 53.3]	69.5 ± 2.8 [63.4, 74.5]	71.0 ± 2.8 [65.7, 76.5]	70.3 ± 2.1 [66.4, 74.2]	70.7 ± 2.8 [66.1, 76.6]	69.8 ± 2.7 [64.8, 75.1]	2.42 ± 0.27 [1.99, 3.09]	0.43 ± 0.04 [0.35, 0.52]	5.74 ± 1.18 [3.90, 8.40]
			RNN-AD	49.5 ± 2.0 [46.3, 53.9]	68.8 ± 2.6 [64.3, 73.7]	69.9 ± 2.6 [65.2, 74.8]	69.4 ± 1.8 [66.2, 72.6]	69.7 ± 2.8 [65.0, 75.0]	69.0 ± 2.3 [64.8, 73.5]	2.31 ± 0.23 [1.94, 2.78]	0.45 ± 0.04 [0.38, 0.52]	5.24 ± 0.92 [3.83, 7.02]
MCI probably due to AD or mild AD (MMSE)	Patients with MMSE change greater than 0.9 pt in 3 years	50.4 ± 0.3 [49.7, 51.0]	APOE-ε4 carriers	39.1 ± 0.2 [38.7, 39.4]	48.1 ± 0.4 [47.3, 48.8]	70.1 ± 0.4 [69.5, 71.1]	59.1 ± 0.4 [58.5, 59.9]	62.1 ± 0.6 [61.0, 63.3]	57.1 ± 0.5 [56.1, 57.9]	1.61 ± 0.04 [1.56, 1.68]	0.74 ± 0.01 [0.72, 0.76]	2.18 ± 0.08 [2.06, 2.33]
			AD Course Map	49.2 ± 0.3 [48.6, 49.9]	63.6 ± 0.6 [62.4, 64.5]	65.4 ± 0.5 [64.3, 66.5]	64.5 ± 0.4 [63.6, 65.3]	65.2 ± 0.5 [64.2, 66.1]	63.9 ± 0.6 [62.7, 65.0]	1.84 ± 0.04 [1.77, 1.91]	0.56 ± 0.01 [0.54, 0.58]	3.31 ± 0.13 [3.06, 3.54]
			RNN-AD	44.7 ± 0.4 [44.1, 45.4]	54.6 ± 0.6 [53.5, 55.6]	65.4 ± 0.6 [64.3, 66.5]	60.0 ± 0.5 [59.0, 60.8]	61.6 ± 0.6 [60.6, 62.6]	58.6 ± 0.5 [57.4, 59.6]	1.58 ± 0.04 [1.51, 1.64]	0.69 ± 0.01 [0.67, 0.72]	2.28 ± 0.09 [2.09, 2.44]

**Supplementary Table 4** Classification metrics for the identification of fast progressors at entry into a trial. Data are presented as mean value ± SD, with empirical 95% CI. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file. NPV: negative predictive value, LR: likelihood ratio, DOR: diagnostic odds ratio.

Trial	APOE-ε4 carriers	Selection with RNN-AD	Selection with AD Course Map
Participants at risk of AD onset (MMSE)	/	-40.6 ± 7.2 [-53.6, -28.0]	-50.2 ± 7.1 [-62.3, -33.3]
Preclinical AD with high brain amyloid levels (ADAS-Cog13)	-6.4 ± 5.8 [-16.2, 4.9]	-20.5 ± 8.2 [-34.0, -5.6]	-40.9 ± 4.9 [-49.0, -30.1]
Early AD with high brain amyloid levels (CDR-SB)	-13.0 ± 1.8 [-16.3, -9.0]	-38.1 ± 1.7 [-41.4, -34.3]	-38.1 ± 1.6 [-40.9, -35.1]
Early AD with high brain amyloid levels (MMSE)	-5.2 ± 2.3 [-9.4, -0.2]	-42.1 ± 2.2 [-45.8, -37.6]	-45.4 ± 2.0 [-49.3, -41.3]
Early AD with high brain tau levels (ADAS-Cog13)	-24.5 ± 3.4 [-30.5, -18.0]	-41.2 ± 3.9 [-49.5, -34.7]	-44.6 ± 3.9 [-52.2, -37.5]
MCI probably due to AD or mild AD (MMSE)	-37.7 ± 0.9 [-39.5, -35.9]	-37.3 ± 1.1 [-39.2, -34.6]	-43.1 ± 0.8 [-44.7, -41.4]

**Supplementary Table 5** Sample size ratio (in %) of enriched trials compared to sample size of trial without enrichment for a theoretical treatment effect of 25%. Enrichment with AD Course Map always outperforms enrichment based on alternatives; the corresponding sample size reductions range from 38% to 50%. Data are presented as mean value ± standard deviation, with empirical 95% confidence interval. Statistics are computed for n=100 resampling of the validation set (see Methods). Source data are provided as a Source Data file (the same data as for the Figure 6).

Biomarker	ADNI	AIBL	J-ADNI	MEMENTO	PHARMACOG
Cortical-summary SUVR on Amyloid PET (Florbetapir)	$300.66 x - 208.84$	/	/	/	/
Cortical-summary SUVR on Amyloid PET (Florbetaben)	$244.20 x - 170.80$	/	/	/	/
Abeta <sub>1-42</sub> level in CSF	$\frac{x - 1256.69}{536.74}$	$\frac{x - 592.77}{238.71}$	$\frac{x - 396.82}{125.04}$	$\frac{x - 1082.91}{365.57}$	$\frac{x - 816.72}{249.11}$
p-Tau <sub>181</sub> level in CSF	$\frac{x - 24.17}{13.56}$	$\frac{x - 69.56}{23.86}$	$\frac{x - 52.25}{21.08}$	$\frac{x - 63.41}{29.41}$	$\frac{x - 63.93}{34.19}$
Total Tau level in CSF	$\frac{x - 257.53}{122.93}$	$\frac{x - 530.07}{236.23}$	/	$\frac{x - 399.06}{268.13}$	$\frac{x - 439.96}{338.91}$

**Supplementary Table 6** Harmonization equations for CSF and Amyloid PET biomarkers when available. The CSF equations result from the cohort-wise adjustment model described in Methods section.

Biomarker group	Biomarker	Positivity cutoff
Amyloid	Abeta <sub>1-42</sub> level in CSF	< -0.5 (§)
	Cortical summary SUVR on Amyloid PET	> 30 CL
Tau	p-Tau <sub>181</sub> level in CSF	> -0.1 (§)
	Cortical summary SUVR on Tau PET	> 1.55
Neurodegeneration	Total Tau level in CSF	> 0 (§)
	Normalized hippocampus volume	< 0.47 (% ICV)
Cognition / Clinical	CDR Global	C- [CDR = 0] C~ [CDR = 0.5] C+ [CDR ≥ 1]

**Supplementary Table 7** Biomarker cutoff points for defining A(myloid)/T(au)/N(eurodegeneration)/C(linical) profiles. For biomarker groups with multiple possible biomarkers, we considered the group to be positive if at least one biomarker was positive. We grouped very rare A/T/N/C combinations (less than 0.5%) together or under more frequent profiles. (§) Value in harmonized units (see Methods). CL: Centiloid Scale. ICV: Intracranial volume.

**Supplementary Table 8** Characteristics of participants included in the six simulated trials. ARC: annual rate of change. N.C.: not disclosed. Format for non-constant continuous variables: mean  $\pm$  standard deviation [95% confidence interval] (% available).

(a) Participants at risk of AD onset (MMSE)

	Pooled	ADNI	AIBL	J-ADNI	MEMENTO
Number of forecasts	197	110	19	5	63
Number of subjects	69	38	9	5	17
Number of forecasts per subject	2.9 $\pm$ 1.9 [1, 6]	2.9 $\pm$ 2.0 [1, 6]	2.1 $\pm$ 1.1 [1, 3]	1.0 $\pm$ 0.0 [1, 1]	3.7 $\pm$ 1.8 [1, 6]
Trial duration (y)	3.6 $\pm$ 0.6 [3.0, 4.8]	3.8 $\pm$ 0.6 [3.0, 4.9]	3.4 $\pm$ 0.7 [3.0, 4.5]	3.0 $\pm$ 0.0 [3.0, 3.0]	3.5 $\pm$ 0.4 [3.0, 4.2]
Age at screening	70.1 $\pm$ 4.2 [61.7, 75.9]	71.0 $\pm$ 3.3 [65.4, 75.9]	65.9 $\pm$ 3.0 [62.0, 71.5]	65.2 $\pm$ 4.3 [60.1, 68.9]	70.3 $\pm$ 5.0 [61.1, 75.9]
Female	64.0%	60.9%	57.9%	40.0%	73.0%
<b>Education level</b>					
≤ 9 years	7.6%	0.9%	15.8%		17.5%
Between 10 and 15 years	41.6%	35.5%	63.2%	60.0%	44.4%
≥ 16 years	49.7%	63.6%	21.1%	40.0%	34.9%
Missing	1.0%				3.2%
<b>APOE-ε4 copies</b>					
1	73.1%	91.8%	21.1%	60.0%	57.1%
2	26.9%	8.2%	78.9%	40.0%	42.9%
<b>A/T/N/C profile at inclusion</b>					
A-T-N-C-	4.1%	1.8%			9.5%
A*T*N*C-	18.3%	1.8%	78.9%	40.0%	27.0%
A+T-N-C-	49.2%	55.5%	15.8%	60.0%	47.6%
A+T+N-C-	12.7%	20.0%	5.3%		3.2%
A+T+N+C-	15.7%	20.9%			12.7%
<b>Score distribution at inclusion</b>					
CDR (global)			0		
CDR-SB	0.0 $\pm$ 0.1 [0.0, 0.5] (97.5 %)	0.0 $\pm$ 0.1 [0.0, 0.5]	0.0 $\pm$ 0.0 [0.0, 0.0]	N.C.	0.1 $\pm$ 0.2 [0.0, 0.5]
MMSE	28.9 $\pm$ 1.1 [26.0, 30.0]	28.9 $\pm$ 1.1 [27.0, 30.0]	28.8 $\pm$ 1.2 [26.4, 30.0]	28.8 $\pm$ 1.6 [26.3, 30.0]	28.8 $\pm$ 1.1 [26.6, 30.0]
ADAS-Cog13	8.2 $\pm$ 4.1 [1.6, 15.7] (55.8 %)	8.2 $\pm$ 4.1 [1.6, 15.7]	/	N.C.	/
<b>ARC distribution</b>					
Annual rate of change CDR-SB	0.1 $\pm$ 0.3 [0.0, 0.9] (97.0 %)	0.2 $\pm$ 0.3 [0.0, 1.1] (94.5 %)	0.0 $\pm$ 0.0 [0.0, 0.0]	0.1 $\pm$ 0.2 [0.0, 0.4]	0.1 $\pm$ 0.2 [0.0, 0.6]
Annual rate of change MMSE	-0.1 $\pm$ 0.5 [-1.7, 0.7]	-0.2 $\pm$ 0.6 [-1.7, 0.7]	0.1 $\pm$ 0.5 [-1.0, 0.7]	-0.5 $\pm$ 0.8 [-1.6, 0.3]	-0.1 $\pm$ 0.5 [-1.5, 0.6]
Annual rate of change ADAS-Cog13	0.6 $\pm$ 1.6 [-1.3, 4.3] (56.9 %)	0.6 $\pm$ 1.5 [-1.3, 4.0] (97.3 %)	/	0.6 $\pm$ 2.4 [-1.2, 4.3]	/

## (b) Preclinical AD with high brain amyloid levels (ADAS-Cog13)

	Pooled	ADNI	J-ADNI
Number of forecasts	434	426	8
Number of subjects	126	118	8
Number of forecasts per subject	3.4 ± 2.9 [1, 12]	3.6 ± 2.9 [1, 12]	1.0
Trial duration (y)	3.9 ± 0.6 [3.0, 5.0]	3.9 ± 0.6 [3.0, 5.0]	3.0 ± 0.0 [3.0, 3.0]
Age at screening	74.8 ± 4.4 [65.4, 80.8]	74.9 ± 4.3 [65.7, 80.8]	67.9 ± 5.2 [61.5, 77.2]
Female	53.9 %	54.2 %	37.5 %
<b>Education level</b>			
≤ 9 years	1.6%	1.6%	
Between 10 and 15 years	30.2%	29.8%	50.0%
≥ 16 years	68.2%	68.5%	50.0%
<b>APOE-ε4 copies</b>			
0	59.4%	59.6%	50.0%
1	36.9%	36.6%	50.0%
2	3.7%	3.8%	
<b>A/T/N/C profile at inclusion</b>			
A+T-N-C-	53.7%	53.3%	75.0%
A+T+N-C-	15.0%	15.0%	12.5%
A+T+N+C-	31.3%	31.7%	12.5%
<b>Score distribution at inclusion</b>			
CDR (global)		0	
CDR-SB	0.1 ± 0.2 [0.0, 0.5] (98.2 %)	0.1 ± 0.2 [0.0, 0.5]	N.C.
MMSE	29.2 ± 0.9 [27.0, 30.0]	29.2 ± 0.9 [27.0, 30.0]	29.2 ± 0.7 [28.2, 30.0]
ADAS-Cog13	8.3 ± 4.2 [1.0, 16.8] (98.2 %)	8.3 ± 4.2 [1.0, 16.8]	N.C.
<b>ARC distribution</b>			
Annual rate of change CDR-SB	0.2 ± 0.3 [0.0, 1.1] (96.5 %)	0.2 ± 0.3 [0.0, 1.1] (96.5 %)	0.0 ± 0.0 [0.0, 0.0]
Annual rate of change MMSE	-0.2 ± 0.6 [-1.3, 0.6] (99.5 %)	-0.2 ± 0.6 [-1.4, 0.6] (99.5 %)	-0.0 ± 0.5 [-0.9, 0.6]
Annual rate of change ADAS-Cog13	0.7 ± 1.5 [-1.5, 3.8]	0.7 ± 1.5 [-1.5, 3.9]	-0.4 ± 1.0 [-1.4, 1.5]

(c) Early AD with high brain amyloid levels (MMSE)

	Pooled	ADNI	AIBL	J-ADNI	MEMENTO	PHARMACOG
Number of forecasts	3,371	1,872	6	371	709	413
Number of subjects	895	581	5	66	167	76
Number of forecasts per subject	3.8 ± 2.6 [1, 10]	3.2 ± 2.2 [1, 8]	1.2 ± 0.4 [1, 2]	5.6 ± 2.8 [1, 9]	4.2 ± 3.0 [1, 11]	5.4 ± 2.8 [1, 12]
Trial duration (y)	1.4 ± 0.4 [1.0, 2.0]	1.4 ± 0.4 [1.0, 2.0]	1.5 ± 0.0 [1.5, 1.5]	1.4 ± 0.4 [1.0, 2.0]	1.4 ± 0.3 [1.0, 2.0]	1.3 ± 0.4 [1.0, 2.0]
Age at screening	73.3 ± 6.7 [59.5, 84.5]	74.0 ± 6.7 [59.7, 84.8]	76.9 ± 3.8 [72.2, 82.6]	72.8 ± 5.6 [62.0, 83.0]	73.0 ± 7.0 [56.3, 83.7]	71.0 ± 6.3 [57.2, 82.5]
Female	45.6%	41.0%	50.0%	46.1%	50.2%	57.9%
<b>Education level</b>						
≤ 9 years	11.7%	0.8%	50.0%	11.1%	24.0%	40.2%
Between 10 and 15 years	38.5%	33.1%	16.7%	52.3%	49.6%	32.0%
≥ 16 years	49.3%	66.1%	33.3%	36.7%	24.3%	27.8%
Missing	0.4%				2.1%	
<b>APOE-ε4 copies</b>						
0	36.0%	39.2%	50.0%	32.9%	33.0%	29.1%
1	48.7%	44.7%	33.3%	54.2%	52.3%	55.9%
2	13.6%	15.8%	16.7%	12.9%	9.3%	12.1%
Missing	1.7%	0.3%			5.4%	2.9%
<b>A/T/N/C profile at inclusion</b>						
A+T-N-C~	17.9%	24.1%		7.0%	9.4%	14.3%
A+T-N+C~	12.5%	8.2%		15.1%	16.8%	22.5%
A+T+N-C~	10.5%	13.8%	33.3%	8.1%	3.1%	10.2%
A+T+N+C~	56.8%	52.8%	33.3%	69.0%	63.5%	53.0%
A+T*N*C~	2.3%	1.1%	33.3%	0.8%	7.2%	
<b>Score distribution at inclusion</b>						
CDR (global)				0.5		
CDR-SB	1.5 ± 1.0 [0.0, 4.0] (76.7 %)	1.6 ± 1.1 [0.0, 4.0]	2.2 ± 1.8 [0.1, 4.4]	N.C.	1.1 ± 0.9 [0.0, 3.5]	/
MMSE	27.3 ± 1.9 [24.0, 30.0]	27.5 ± 1.9 [24.0, 30.0]	26.5 ± 1.5 [25.0, 28.8]	26.4 ± 1.7 [24.0, 30.0]	27.4 ± 1.8 [24.0, 30.0]	26.6 ± 1.7 [24.0, 30.0]
ADAS-Cog13	17.2 ± 7.4 [4.0, 31.3] (67.7 %)	16.6 ± 7.4 [3.7, 31.0] (99.9 %)	/	N.C.	/	19.7 ± 6.6 [6.7, 33.9] (99.8 %)
<b>ARC distribution</b>						
Annual rate of change CDR-SB	0.6 ± 1.1 [-1.0, 3.3] (85.8 %)	0.5 ± 1.1 [-1.0, 3.1] (98.9 %)	0.5 ± 1.1 [-0.9, 2.2]	0.9 ± 1.2 [-1.0, 3.8]	0.5 ± 1.1 [-0.9, 3.4] (93.7 %)	/
Annual rate of change MMSE	-0.9 ± 2.0 [-5.6, 2.0]	-0.8 ± 2.0 [-5.5, 2.1]	-0.8 ± 1.8 [-3.2, 0.7]	-1.7 ± 1.9 [-5.9, 2.0]	-0.8 ± 1.9 [-5.3, 1.9]	-0.7 ± 2.0 [-6.0, 2.0]
Annual rate of change ADAS-Cog13	1.8 ± 4.3 [-5.5, 11.7] (77.9 %)	1.7 ± 4.4 [-5.8, 12.0] (99.0 %)	/	2.4 ± 3.7 [-4.3, 10.0]	/	1.6 ± 3.9 [-5.1, 11.0] (97.1 %)

## (d) Early AD with high brain amyloid levels (CDR-SB)

	Pooled	ADNI	AIBL	J-ADNI	MEMENTO
Number of forecasts	2,934	1,894	6	371	663
Number of subjects	824	589	5	66	164
Number of forecasts per subject	3.6 ± 2.5 [1, 9]	3.2 ± 2.3 [1, 9]	1.2 ± 0.4 [1, 2]	5.6 ± 2.8 [1, 9]	4.0 ± 2.9 [1, 10]
Trial duration (y)	1.4 ± 0.4 [1.0, 2.0]	1.4 ± 0.4 [1.0, 2.0]	1.5 ± 0.0 [1.5, 1.5]	1.4 ± 0.4 [1.0, 2.0]	1.4 ± 0.3 [1.0, 2.0]
Age at screening	73.7 ± 6.7 [59.6, 84.6]	74.1 ± 6.7 [59.9, 84.9]	76.9 ± 3.8 [72.2, 82.6]	72.8 ± 5.6 [62.0, 83.0]	72.9 ± 7.1 [56.2, 84.0]
Female	43.0%	40.2%	50.0%	46.1%	49.3%
<b>Education level</b>					
≤ 9 years	7.7%	0.8%	50.0%	11.1%	25.0%
Between 10 and 15 years	38.6%	32.9%	16.7%	52.3%	47.2%
≥ 16 years	53.2%	66.3%	33.3%	36.7%	25.5%
Missing	0.5%				2.3%
<b>APOE-ε4 copies</b>					
0	37.0%	38.9%	50.0%	32.9%	33.6%
1	47.4%	44.8%	33.3%	54.2%	51.3%
2	14.1%	15.9%	16.7%	12.9%	9.4%
Missing	1.5%	0.4%			5.7%
<b>A/T/N/C profile at inclusion</b>					
A+T-N-C~	18.5%	24.0%		7.0%	9.4%
A+T-N+C~	11.0%	7.9%		15.1%	17.5%
A+T+N-C~	10.8%	13.9%	33.3%	8.1%	3.3%
A+T+N+C~	57.1%	53.0%	33.3%	69.0%	62.3%
A+T*N*C~	2.7%	1.3%	33.3%	0.8%	7.5%
<b>Score distribution at inclusion</b>					
CDR (global)			0.5		
CDR-SB	1.5 ± 1.0 [0.0, 4.0] (87.4 %)	1.6 ± 1.1 [0.0, 4.0]	2.2 ± 1.8 [0.1, 4.4]	N.C.	1.1 ± 0.9 [0.0, 3.5]
MMSE	27.3 ± 1.9 [24.0, 30.0]	27.5 ± 1.9 [24.0, 30.0]	26.5 ± 1.5 [25.0, 28.8]	26.4 ± 1.7 [24.0, 30.0]	27.4 ± 1.8 [24.0, 30.0]
ADAS-Cog13	16.7 ± 7.5 [3.7, 31.2] (64.5 %)	16.7 ± 7.5 [3.7, 31.2] (99.9 %)	/	N.C.	/
<b>ARC distribution</b>					
Annual rate of change CDR-SB	0.6 ± 1.1 [-1.0, 3.3]	0.6 ± 1.1 [-1.0, 3.3]	0.5 ± 1.1 [-0.9, 2.2]	0.9 ± 1.2 [-1.0, 3.8]	0.5 ± 1.1 [-1.0, 3.6]
Annual rate of change MMSE	-1.0 ± 2.0 [-5.5, 2.0] (98.1 %)	-0.8 ± 2.0 [-5.5, 2.1] (97.4 %)	-0.8 ± 1.8 [-3.2, 0.7]	-1.7 ± 1.9 [-5.9, 2.0]	-0.9 ± 1.9 [-5.2, 1.9] (98.8 %)
Annual rate of change ADAS-Cog13	1.8 ± 4.4 [-5.6, 11.7] (75.1 %)	1.7 ± 4.5 [-5.7, 12.0] (96.7 %)	/	2.4 ± 3.7 [-4.3, 10.0]	/



(e) Early AD with high brain tau levels (ADAS-Cog13)

<b>ADNI</b>	
Number of forecasts	488
Number of subjects	170
Number of forecasts per subject	2.9 ± 2.0 [1, 8]
Trial duration (y)	4.4 ± 0.3 [4.0, 5.0]
Age at screening	72.0 ± 5.9 [58.1, 80.5]
Female	41.6%
<b>Education level</b>	
≤ 9 years	1.6%
Between 10 and 15 years	38.5%
≥ 16 years	59.8%
<b>APOE-ε4 copies</b>	
0	41.2%
1	44.7%
2	14.1%
<b>A/T/N/C profile at inclusion</b>	
A+T+N-C~	16.4%
A+T+N+C~	53.3%
A-T+ *	30.3%
<b>Score distribution at inclusion</b>	
CDR (global)	0.5
CDR-SB	1.5 ± 1.0 [0.0, 4.0]
MMSE	27.4 ± 2.2 [22.0, 30.0]
ADAS-Cog13	15.9 ± 6.8 [4.7, 28.6]
<b>ARC distribution</b>	
Annual rate of change CDR-SB	0.5 ± 0.7 [-0.3, 2.3] (98.4 %)
Annual rate of change MMSE	-0.8 ± 1.1 [-3.9, 0.5]
Annual rate of change ADAS-Cog13	2.0 ± 2.8 [-1.6, 9.7]

## (f) MCI probably due to AD or mild AD (MMSE)

	Pooled	ADNI	AIBL	J-ADNI	MEMENTO	PHARMACOG
Number of forecasts	8,570	3,040	165	343	4,996	26
Number of subjects	2,193	711	102	174	1,192	14
Number of forecasts per subject	3.9 ± 2.7 [1, 10]	4.3 ± 2.9 [1, 11]	1.6 ± 0.5 [1, 2]	2.0 ± 0.2 [1, 2]	4.2 ± 2.7 [1, 9]	1.9 ± 1.0 [1, 3]
Trial duration (y)	2.9 ± 0.4 [2.3, 3.6]	3.0 ± 0.4 [2.3, 3.6]	3.0 ± 0.0 [3.0, 3.0]	2.8 ± 0.3 [2.5, 3.0]	2.9 ± 0.4 [2.3, 3.6]	2.6 ± 0.2 [2.5, 3.0]
Age at screening	72.6 ± 7.0 [58.3, 84.7]	73.6 ± 7.0 [59.6, 85.0]	74.2 ± 7.0 [61.0, 85.2]	73.5 ± 5.8 [62.3, 83.2]	71.9 ± 7.1 [57.8, 84.5]	72.3 ± 5.6 [64.4, 82.2]
Female	50.7 %	38.5 %	49.1 %	55.1 %	57.9 %	57.7 %
<b>Education level</b>						
≤ 9 years	14.1 %	1.5 %	23.0 %	12.2 %	21.5 %	53.8 %
Between 10 and 15 years	46.3 %	33.4 %	53.3 %	60.9 %	52.9 %	30.8 %
≥ 16 years	37.8 %	65.1 %	23.6 %	26.8 %	22.5 %	15.4 %
Missing	1.8 %				3.1 %	
<b>APOE-ε4 copies</b>						
0	57.9 %	52.0 %	45.5 %	45.8 %	63.0 %	30.8 %
1	32.1 %	36.5 %	38.2 %	44.9 %	28.1 %	65.4 %
2	7.6 %	11.4 %	16.4 %	8.7 %	4.9 %	3.8 %
Missing	2.4 %			0.6 %	4.0 %	
<b>A/T/N/C profile at inclusion</b>						
A*T*N*C~	57.6%	20.8%	84.8%	60.6%	79.1%	
A+T+N+C~	12.7%	23.4%		18.4%	6.2%	34.6%
A*T*N*C+	2.0%	2.3%	13.3%	2.6%	1.4%	
A+T+N+C+	1.3%	3.8%			0.0%	
A+[T- or N-]C[~ or +]	9.6%	21.0%	1.2%	7.6%	2.9%	53.8%
A-T+ *	4.7%	8.5%	0.6%	2.9%	2.7%	7.7%
A-T*N*C[~ or +]	11.9%	20.3%		7.9%	7.5%	3.8%
<b>Score distribution at inclusion</b>						
CDR (global)	0.5 ± 0.1 [0.5, 1.0]	0.5 ± 0.1 [0.5, 1.0]	0.6 ± 0.2 [0.5, 1.0]	0.5 ± 0.1 [0.5, 1.0]	0.5 ± 0.1 [0.5, 0.5]	0.5 ± 0.0 [0.5, 0.5]
CDR-SB	1.4 ± 1.2 [0.5, 5.0] (95.7 %)	1.9 ± 1.4 [0.5, 5.5]	2.0 ± 1.8 [0.5, 6.0] (99.4 %)	N.C.	1.1 ± 0.9 [0.5, 4.0]	/
MMSE	27.3 ± 2.5 [21.0, 30.0]	27.2 ± 2.7 [21.0, 30.0]	25.5 ± 3.7 [18.0, 30.0]	26.1 ± 2.2 [21.0, 30.0]	27.5 ± 2.2 [22.0, 30.0]	27.4 ± 1.8 [24.0, 30.0]
ADAS-Cog13	16.5 ± 8.2 [3.3, 34.0] (35.7 %)	16.4 ± 8.2 [3.3, 34.0]	/	N.C.	/	19.6 ± 4.1 [11.3, 25.8]
<b>ARC distribution</b>						
Annual rate of change CDR-SB	0.4 ± 0.9 [-0.5, 2.9] (95.9 %)	0.5 ± 0.9 [-0.5, 3.0] (98.2 %)	1.0 ± 1.2 [-0.3, 4.0] (99.4 %)	1.1 ± 1.2 [-0.2, 4.3] (98.3 %)	0.2 ± 0.8 [-0.6, 2.6] (94.7 %)	/
Annual rate of change MMSE	-0.5 ± 1.3 [-4.0, 1.2]	-0.7 ± 1.4 [-4.4, 1.2]	-1.3 ± 1.9 [-6.0, 1.0]	-1.3 ± 1.5 [-5.5, 0.9]	-0.4 ± 1.1 [-3.5, 1.2]	-0.5 ± 0.8 [-1.6, 1.2]
Annual rate of change ADAS-Cog13	1.8 ± 3.1 [-2.3, 10.3] (39.0 %)	1.7 ± 3.1 [-2.4, 10.4]	/	2.7 ± 2.9 [-1.7, 9.8]	/	0.6 ± 1.7 [-1.9, 3.3]

**Supplementary Table 9** The MEMENTO study group

Name	Degree	Location	Role
Michèle Allard	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
Sandrine Andrieu	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
Pierre Anthony	MD, PhD	Memory Resource and Research Centre of Colmar, Hôpitaux Civils de Colmar, F-68000, Colmar, France	Co-investigator
Christine Astier	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
Alexandre Augier	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
Nicolas Auguste	MD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital de la Charité, F-42000, Saint-Etienne, France	Co-investigator
Sophie Auriacombe	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
John Avet	MD, PhD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
Olivier Bailon	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
Fabrice-Guy Barral	MD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
Jean Barré	MD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
Annick Bartheleix	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
Catherine Bayle	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
Olivier Beauchet		Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
Catherine Belin	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
Samia Belkacem	MD	Institute of Memory and Alzheimer's Disease (IM2A), Centre for Neuroimaging Research (CENIR), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
Douraid Ben Salem	MD, PhD	Memory Resource and Research Centre of Brest, CHRU de Brest, F-29000, Brest, France	Co-investigator
Karim Bennys	MD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
Géraldine Bera	MD	Laboratoire d'Imagerie Biomédicale, Sorbonne Universités, UPMC Univ Paris 06, Inserm U1146, CNRS UMR 7371, France NeuroSpin, I2BM, Commissariat à l'Energie Atomique, Paris, France	Co-investigator
Eric Berger	MD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjot, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
Marc G Berger	MD, PhD	Memory Resource and Research Centre of Clermont-Ferrand, CHU de Clermont-Ferrand, F-63000, Clermont-Ferrand, France	Co-investigator
Emilie Bergouin	MD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
François Bertin-Hugault	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
Guillaume Bertrand	MD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
François-Xavier Bertrand	MD, PhD	Memory Resource and Research Centre of Nantes, CHU de Nantes, F-44000, Nantes, France	Co-investigator
Catherine Beze	MD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
Valérie Boilet		Coordinating Centre, Inserm CIC-1401 Clinical Epidemiology, CHU de Bordeaux, F-33000, Bordeaux, France	Co-investigator
Stéphanie Bombois	MD, PhD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
Alain Bonafé	MD, PhD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Montpellier, France	Co-investigator
Yasmina Boudali	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
Hatem Bouhladour	MD, PhD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjot, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
Clémence Bouilly	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator

<b>Isabelle Bourdel-Marchasson</b>	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
<b>Vincent Bouteloup</b>	PharmD	Coordinating Centre, Inserm CIC-1401 Clinical Epidemiology, CHU de Bordeaux, F-33000, Bordeaux, France	Co-investigator
<b>Claire Boutet</b>	MD	Institute of Memory and Alzheimer's Disease (IM2A), Centre for Neuroimaging Research (CENIR), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Serge Bracard</b>	MD, PhD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator
<b>Antoine Brangier</b>	MD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Pierre-Yves Brillet</b>	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Laure Caillard</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Fabienne Calvas</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Agnès Camus</b>	MD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Vincent Camus</b>	MD, PhD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>Sandrine Canaple</b>	MD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Antoine Carpentier</b>	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Pascaline Cassagnaud</b>	MD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Françoise Cattin</b>	MD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjoz, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
<b>Ludivine Chamard</b>	MD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjoz, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
<b>Stéphane Chanalet</b>	MD	Memory Resource and Research Centre of Nice, CHU de Nice, Hôpital Pasteur, F-06100, Nice, France	Co-investigator
<b>Mathieu Chastan</b>	MD	Memory Resource and Research Centre of Rouen, CLCC Henri Becquerel, Rouen, France	Co-investigator
<b>Sophie Chauvelier</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Valérie Chauvire</b>	MD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Samia Cheriet</b>	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Anthony Clotagatide</b>	MD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
<b>Emmanuel Cognat</b>	MD, PhD	Memory Resource and Research Centre of Paris Nord, AP-HP, Paris, France	Co-investigator
<b>Lora Cohen</b>	PhD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Jean-Marc Constans</b>	MD, PhD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Marie-Hélène Coste</b>	MD, PhD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Jean-Philippe Cottier</b>	MD, PhD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>François Cotton</b>	MD, PhD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Isabelle Couret</b>	MD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Olivier-François Couturier</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Pascale Cowppli-Bony</b>	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Véronique Cressot</b>	MD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
<b>Benjamin Crétin</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Keren Danaila</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Jacques Darcourt</b>	MD, PhD	Memory Resource and Research Centre of Nice, CLCC Antoine Lacassagne, Nice, France	Co-investigator

<b>Jean-François Dartigues</b>	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Ana-Maria Dascalita</b>	MD, PhD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital de la Charité, F-42000, Saint-Etienne, France	Co-investigator
<b>Renaud David</b>	MD, PhD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Xavier De Petigny</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Delphine De Verbizier-Lonjon</b>	MD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Marielle Decousus</b>	MD, PhD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
<b>Isabelle Defouilloy</b>	MD, PhD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Christine Delmaire</b>	MD, PhD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Julien Delrieu</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Catherine Demuyinck</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Vincent Deramecourt</b>	MD, PhD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Hervé Deramond</b>	MD, PhD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Thomas Desmidt</b>	MD, PhD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>Marie-Dominique Desruet</b>	PharmD, PhD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Julien Detour</b>		Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Agnès Devendeville</b>	MD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Mira Didic</b>	MD, PhD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Maritchu Doireau</b>	MD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Antonio Dos Santos</b>	MD	Institute of Memory and Alzheimer's Disease (IM2A), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Patrice Douillet</b>	MD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Foucaud Du Boisgueheneuc</b>	MD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Delphine Dubail</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Laure Ducroq-Ducastaing</b>	MD	Memory Resource and Research Centre of Brest, CHRU de Brest, F-29000, Brest, France	Co-investigator
<b>Julien Dumurgier</b>	MD, PhD	Memory Resource and Research Centre of Paris Nord, AP-HP, Paris, France	Co-investigator
<b>Diane Dupuy</b>	MD, PhD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Emmanuelle Duron</b>	MD, PhD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Inna Dygai-Cochet</b>	MD, PhD	Memory Resource and Research Centre of Dijon, CLCC Georges François Leclerc, Dijon, France	Co-investigator
<b>Véronique Eder</b>	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Stéphane Epelbaum</b>	MD, PhD	Institute of Memory and Alzheimer's Disease (IM2A), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Frédérique Etcharry-Bouyx</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Daniel Fagret</b>	MD, PhD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Catherine Faisant</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Karim Farid</b>	MD, PhD	Memory Resource and Research Centre of Paris Nord, AP-HP, Paris, France	Co-investigator
<b>Denis Fédérico</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator

<b>Olivier Felician</b>	MD, PhD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Philippe Fernandez</b>	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Pacôme Fosse</b>	MD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Alexandra Foubert-Samier</b>	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Isabelle Franck</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Monique Galitzky</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Céline Gallazzini-Crepin</b>	MD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Radka Gantchev</b>	MD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Laurence Garbarg-Chenon</b>	MD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Guillaume Gautier</b>	MD, PhD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Emmanuel Gerardin</b>	MD, PhD	Memory Resource and Research Centre of Rouen, Neuroradiology Department, Rouen University Hospital, F-76031, Rouen, France	Co-investigator
<b>Claire Gervais</b>	MD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Jean-Claude Getenet</b>	MD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
<b>Nadine Girard</b>	MD, PhD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Fabienne Giraud</b>	MD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Chantal Girtanner</b>	MD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital de la Charité, F-42000, Saint-Etienne, France	Co-investigator
<b>Valérie Gissot</b>	MD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>Caroline Grangeon</b>	PharmD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Daniel Grucker</b>	MD, PhD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Eric Guedj</b>	MD, PhD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Claude Gueriot</b>	MD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Yves Guilhermet</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Rémy Guillevin</b>	MD, PhD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Sophie Haffen</b>	MD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjot, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
<b>Didier Hannequin</b>	MD, PhD	Memory Resource and Research Centre of Rouen, Neurology Department, Rouen University Hospital, F-76031, Rouen, France	Co-investigator
<b>Sandrine Harston</b>	MD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
<b>Anne Hitzel</b>	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Caroline Hommet</b>	MD, PhD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>Claude Hossein-Foucher</b>	MD, PhD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Fabrice Hubele</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Agnès Jacquin-Piques</b>	MD, PhD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Betty Jean</b>	MD	Memory Resource and Research Centre of Clermont-Ferrand, CHU de Clermont-Ferrand, F-63000, Clermont-Ferrand, France	Co-investigator
<b>Joanne Jenn</b>	MD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
<b>Laure Joly</b>	MD, PhD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator
<b>Thérèse Jonveaux</b>	MD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator

<b>Adrien Julian</b>	MD, PhD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Aurélie Kas</b>	MD, PhD	Laboratoire d'Imagerie Biomédicale, Sorbonne Universités, UPMC Univ Paris 06, Inserm U1146, CNRS UMR 7371, France NeuroSpin, I2BM, Commissariat à l'Energie Atomique, Paris, France	Co-investigator
<b>Anna Kearney-Schwartz</b>	MD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator
<b>Alice Keles</b>	MD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator
<b>Antony Kelly</b>	MD	Memory Resource and Research Centre of Clermont-Ferrand, Centre de Lutte contre le Cancer, F-63000, Clermont-Ferrand, France	Co-investigator
<b>Nathalie Keromnes</b>	MD	Memory Resource and Research Centre of Brest, CHRU de Brest, F-29000, Brest, France	Co-investigator
<b>Lejla Koric</b>	MD	Memory Resource and Research Centre of Marseille, CHU de Marseille, Hôpital La Timone, F-13000, Marseille, France	Co-investigator
<b>Alexandre Krainik</b>	MD, PhD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Stéphane Kremer</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Florian Labourée</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Franck Lacoeuille</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Francoise Lala</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Chantal Lamy</b>	MD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Jean-Louis Laplanche</b>	PharmD, PhD	Memory Resource and Research Centre of Paris Nord, AP-HP, Paris, France	Co-investigator
<b>Cyrille Launay</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Stéphane Lehericy</b>	MD, PhD	Institute of Memory and Alzheimer's Disease (IM2A), Centre for Neuroimaging Research (CENIR), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Sylvain Lehmann</b>	MD, PhD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Hermine Lenoir</b>	MD, PhD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Marcel Levy</b>	MD, PhD	Institute of Memory and Alzheimer's Disease (IM2A), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Stéphanie Libercier</b>	MD, PhD	Memory Resource and Research Centre of Colmar, Hôpitaux Civils de Colmar, F-68000, Colmar, France	Co-investigator
<b>Marie-Anne Mackowiak-Cordoliani</b>	MD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Eloi Magnin</b>	MD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjoz, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
<b>Zaza Makaroff</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Athina Marantidou</b>	MD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Isabelle Marcet</b>	MD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Cécilia Marelli</b>	MD, PhD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Sophie Marilier</b>	MD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Idalie Martin</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Olivier Martinaud</b>	MD, PhD	Memory Resource and Research Centre of Rouen, Neurology Department, Rouen University Hospital, F-76031, Rouen, France	Co-investigator
<b>Catherine Martin-Hunyadi</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Aïcha Medjoul</b>	MD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Isabelle Merlet</b>	MD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Danielle Mestas</b>	MD	Memory Resource and Research Centre of Clermont-Ferrand, CHU de Clermont-Ferrand, F-63000, Clermont-Ferrand, France	Co-investigator

<b>Marc-Etienne Meyer</b>	MD, PhD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Jean-Marc Michel</b>	MD	Memory Resource and Research Centre of Colmar, Hôpitaux Civils de Colmar, F-68000, Colmar, France	Co-investigator
<b>Agnès Michon</b>	MD	Institute of Memory and Alzheimer's Disease (IM2A), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Isabelle Migeon-Duballet</b>	MD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Karl Mondon</b>	MD, PhD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>Clément Morgat</b>	PharmD, PhD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, F-33000, Bordeaux, France	Co-investigator
<b>Véronique Moullart</b>	MD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Christian Moussard</b>	MD	Memory Resource and Research Centre of Besançon, CHU de Besançon, Hôpital Jean Minjot, Hôpital Saint-Jacques, F-25000, Besançon, France	Co-investigator
<b>Aurélie Mouton</b>	MD, PhD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Izzie Jacques Namer</b>	MD, PhD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Georges Niewiadomski</b>	MD, PhD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Guillaume Nivaggioni</b>	MD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Marie Noblet</b>	MD, PhD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Michel Nonent</b>	MD, PhD	Memory Resource and Research Centre of Brest, CHRU de Brest, F-29000, Brest, France	Co-investigator
<b>Fati Nourhashemi</b>	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Hélène Oesterle</b>	MD	Memory Resource and Research Centre of Colmar, Hôpitaux Civils de Colmar, F-68000, Colmar, France	Co-investigator
<b>Galdric Orvoen</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Pierre Jean Ousset</b>	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Amandine Pallardy</b>	MD	Memory Resource and Research Centre of Nantes, CHU de Nantes, F-44000, Nantes, France	Co-investigator
<b>Claire Paquet</b>	MD, PhD	Memory Resource and Research Centre of Paris Nord, AP-HP, Paris, France	Co-investigator
<b>Pierre-Yves Pare</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Anne Pasco</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Pierre Payoux</b>	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Cécile Pays</b>	MD, PhD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Isabelle Pellegrin</b>	MD, PhD	Biological Research Centre, CHU de Bordeaux, F-33000, Bordeaux, France	Co-investigator
<b>Rémy Perdrisot</b>	MD, PhD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Bertille Perin</b>	MD, PhD	Memory Resource and Research of Amiens, CHU Amiens Picardie, F-80000, Amiens, France	Co-investigator
<b>Christine Perret-Guillaume</b>	MD, PhD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator
<b>Grégory Petyt</b>	MD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Nathalie Philippi</b>	MD, PhD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Geneviève Pinganaud</b>	MD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
<b>Matthieu Plichart</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Gabriel Pop</b>	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Michèle Puel</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Mathieu Queneau</b>	MD, PhD	Memory Resource and Research Centre of Paris Nord, Centre Cardiologique du Nord, Paris, France	Co-investigator
<b>Solène Querellou</b>	MD	Memory Resource and Research Centre of Brest, CHRU de Brest, F-29000, Brest, France	Co-investigator



<b>Muriel Quillard-Muraine</b>	MD, PhD	Memory Resource and Research Centre of Rouen, Neurology Department, Rouen University Hospital, F-76031, Rouen, France	Co-investigator
<b>Valérie Quipourt</b>	MD, PhD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Chloé Rachez</b>	MD, PhD	Memory Resource and Research Centre of Clermont-Ferrand, CHU de Clermont-Ferrand, F-63000, Clermont-Ferrand, France	Co-investigator
<b>Micheline Razzouk-Cadet</b>	MD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Anne-Sophie Rigaud</b>	MD, PhD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Hélène Robin-Ismer</b>	MD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Mathieu Rodallec</b>	MD, PhD	Memory Resource and Research Centre of Paris Nord, Centre Cardiologique du Nord, Paris, France	Co-investigator
<b>Yves Rolland</b>	MD, PhD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Adeline Rollin-Sillaire</b>	MD, PhD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Olivier Rouaud</b>	MD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Caroline Roubaud</b>	MD, PhD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Isabelle Rouch</b>	MD, PhD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Julie Roux</b>	MD, PhD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Guillaume Sacco</b>	MD, PhD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Pierre-Yves Salaun</b>	MD	Memory Resource and Research Centre of Brest, CHRU de Brest, F-29000, Brest, France	Co-investigator
<b>François Salmon</b>	MD, PhD	Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Hôpital de La Milétrie, F-86000, Poitiers, France	Co-investigator
<b>Alicia Sanchez</b>	MD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
<b>Maria-Joao Santiago-Ribeiro</b>	MD, PhD	Memory Resource and Research Centre of Center Region, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, France	Co-investigator
<b>Alain Sarciron</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Nathalie Sastre-Hengan</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Mathilde Sauvée</b>	MD, PhD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Christian Scheiber</b>	MD, PhD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Anne-Marie Schneider</b>	MD, PhD	Memory Resource and Research Centre of Strasbourg, Hôpitaux Universitaires de Strasbourg, F-67000, Strasbourg, France	Co-investigator
<b>Franck Semah</b>	MD, PhD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Amélie Serra</b>	MD	Memory Resource and Research Centre of Grenoble, CHU de Grenoble Alpes, Grenoble, France	Co-investigator
<b>Marie-Laure Seux</b>	MD	Memory Resource and Research Centre of Paris Broca, AP-HP, Paris, France	Co-investigator
<b>Hélène Sordet-Guépet</b>	MD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Maria Eugenia Soto</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Mathieu Tafani</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Jean-Yves Tanguy</b>	MD, PhD	Memory Resource and Research Centre of Angers, CHU d'Angers, F-49000, Angers	Co-investigator
<b>Michael Taroux</b>	MD, PhD	Memory Resource and Research Centre of Dijon, CHU Dijon Bourgogne, Hôpital du Bocage, Hôpital de Champmaillot, F-21000, Dijon, France	Co-investigator
<b>Marc Teichmann</b>	MD, PhD	Institute of Memory and Alzheimer's Disease (IM2A), Brain and Spine Institute (ICM), UMR S 1127, Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France	Co-investigator
<b>Catherine Terrat</b>	MD, PhD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital de la Charité, F-42000, Saint-Etienne, France	Co-investigator
<b>Jamila Thabet</b>	MD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator

<b>Claire Thalamas</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital Purpan, F-31000, Toulouse, France	Co-investigator
<b>Catherine Thomas-Anterion</b>	MD, PhD	Memory Resource and Research Centre of Saint-Etienne, CHU de Saint-Etienne, Hôpital Nord, F-42000, Saint-Etienne, France	Co-investigator
<b>Anne-Cécile Troussière</b>	MD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Renata Ursu</b>	MD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator
<b>Pierre Vera</b>	MD, PhD	Memory Resource and Research Centre of Rouen, CLCC Henri Becquerel, Rouen, France	Co-investigator
<b>Martine Vercelletto</b>	MD	Memory Resource and Research Centre of Nantes, CHU de Nantes, F-44000, Nantes, France	Co-investigator
<b>Olivier Vercruyse</b>	MD	Memory Resource and Research Centre of Lille, CHRU de Lille, Hôpital Roger Salengro, F-59000, Lille, France	Co-investigator
<b>Antoine Verger</b>	MD, PhD	Memory Resource and Research Centre of Nancy, CHU de Nancy, F-54000, Nancy, France	Co-investigator
<b>Philippe Viau</b>	MD	Memory Resource and Research Centre of Nice, CHU de Nice, Institut Claude Pompidou, F-06100, Nice, France	Co-investigator
<b>Marie-Neige Videau</b>	MD	Memory Resource and Research Centre of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnoz, F-33000, Bordeaux, France	Co-investigator
<b>Thierry Voisin</b>	MD	Memory Resource and Research Centre of Toulouse, CHU de Toulouse, Hôpital La Grave-Casselardit, F-31000, Toulouse, France	Co-investigator
<b>Nathalie Wagemann</b>	MD, PhD	Memory Resource and Research Centre of Nantes, CHU de Nantes, F-44000, Nantes, France	Co-investigator
<b>Aziza Waissi-Sediq</b>	MD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Jing Xie</b>	MD, PhD	Memory Resource and Research Centre of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, F-69000, Lyon, France	Co-investigator
<b>Nathanaëlle Yeni</b>	MD	Laboratoire d'Imagerie Biomédicale, Sorbonne Universités, UPMC Univ Paris 06, Inserm U1146, CNRS UMR 7371, France NeuroSpin, I2BM, Commissariat à l'Energie Atomique, Paris, France	Co-investigator
<b>Michel Zanca</b>	MD, PhD	Memory Resource and Research Centre of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, F-34000, Montpellier, France	Co-investigator
<b>Jean Zinszner</b>	MD, PhD	Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires Paris-Seine-Saint-Denis, F-93009, Bobigny, France	Co-investigator